WO2018177151A1 - Compounds modulating activity of farnesoid x receptor and methods for the use thereof - Google Patents
Compounds modulating activity of farnesoid x receptor and methods for the use thereof Download PDFInfo
- Publication number
- WO2018177151A1 WO2018177151A1 PCT/CN2018/079472 CN2018079472W WO2018177151A1 WO 2018177151 A1 WO2018177151 A1 WO 2018177151A1 CN 2018079472 W CN2018079472 W CN 2018079472W WO 2018177151 A1 WO2018177151 A1 WO 2018177151A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- fxr
- compound
- ene
- biphenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 140
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 title claims abstract description 92
- 102100038495 Bile acid receptor Human genes 0.000 title claims abstract description 91
- 238000000034 method Methods 0.000 title claims abstract description 26
- 230000000694 effects Effects 0.000 title abstract description 34
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 241000124008 Mammalia Species 0.000 claims abstract description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 12
- 230000001404 mediated effect Effects 0.000 claims abstract description 10
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 9
- 208000019423 liver disease Diseases 0.000 claims abstract description 8
- 208000008589 Obesity Diseases 0.000 claims abstract description 6
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 6
- 235000020824 obesity Nutrition 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 3
- 210000004185 liver Anatomy 0.000 claims description 43
- 239000003981 vehicle Substances 0.000 claims description 21
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 12
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 12
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 10
- 108010082126 Alanine transaminase Proteins 0.000 claims description 10
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 10
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 10
- 231100000753 hepatic injury Toxicity 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 201000005569 Gout Diseases 0.000 claims description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical group NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 8
- -1 methoxy, methyl Chemical group 0.000 claims description 8
- 206010008635 Cholestasis Diseases 0.000 claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 7
- 230000007870 cholestasis Effects 0.000 claims description 6
- 231100000359 cholestasis Toxicity 0.000 claims description 6
- 206010009887 colitis Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 4
- 230000001066 destructive effect Effects 0.000 claims description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 208000037157 Azotemia Diseases 0.000 claims description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 3
- 208000033626 Renal failure acute Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 201000011040 acute kidney failure Diseases 0.000 claims description 3
- 208000012998 acute renal failure Diseases 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 201000006334 interstitial nephritis Diseases 0.000 claims description 3
- 230000011164 ossification Effects 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 3
- 231100001028 renal lesion Toxicity 0.000 claims description 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 3
- 208000009852 uremia Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims description 2
- 208000012868 Overgrowth Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 230000003387 muscular Effects 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 6
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 125000001165 hydrophobic group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- BZZQEJXKEIYOPE-UHFFFAOYSA-N [amino(ethoxy)amino]-methoxymethanol Chemical compound OC(N(N)OCC)OC BZZQEJXKEIYOPE-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 claims 2
- KNVOKRPGYOIUJA-UHFFFAOYSA-N 1-N-[2-fluoro-4-(3-methoxyphenyl)phenyl]cyclopentene-1,2-dicarboxamide Chemical compound C1(=C(CCC1)C(=O)N)C(=O)NC1=C(C=C(C=C1)C1=CC(=CC=C1)OC)F KNVOKRPGYOIUJA-UHFFFAOYSA-N 0.000 claims 1
- ULDLOEYTKJLAIS-UHFFFAOYSA-N 2-[[2-chloro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound ClC=1C=C(C=CC=1NC(=O)C1=C(CCC1)C(=O)O)C1=CC(=CC=C1)OC ULDLOEYTKJLAIS-UHFFFAOYSA-N 0.000 claims 1
- SQOHUOUNTBZXMG-UHFFFAOYSA-N 2-[[2-fluoro-4-(3-methylphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound FC=1C=C(C=CC=1NC(=O)C1=C(CCC1)C(=O)O)C1=CC(=CC=C1)C SQOHUOUNTBZXMG-UHFFFAOYSA-N 0.000 claims 1
- HJKLYPFAVQXTPB-UHFFFAOYSA-N 2-[[2-fluoro-4-(3-propan-2-ylphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound FC=1C=C(C=CC=1NC(=O)C1=C(CCC1)C(=O)O)C1=CC(=CC=C1)C(C)C HJKLYPFAVQXTPB-UHFFFAOYSA-N 0.000 claims 1
- ZWPOZXUSSJZJRN-UHFFFAOYSA-N 2-[[2-methyl-4-(3-methylphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound CC=1C=C(C=CC=1NC(=O)C1=C(CCC1)C(=O)O)C1=CC(=CC=C1)C ZWPOZXUSSJZJRN-UHFFFAOYSA-N 0.000 claims 1
- NYAVFEGBHGSQGC-UHFFFAOYSA-N 2-[[2-methyl-4-(3-propan-2-ylphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound C(C)(C)C=1C=C(C=CC=1)C1=CC(=C(C=C1)NC(=O)C1=C(CCC1)C(=O)O)C NYAVFEGBHGSQGC-UHFFFAOYSA-N 0.000 claims 1
- RMHDGTRLUIJKRY-UHFFFAOYSA-N 2-[[4-(3-ethylphenyl)-2-fluorophenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound C(C)C=1C=C(C=CC=1)C1=CC(=C(C=C1)NC(=O)C1=C(CCC1)C(=O)O)F RMHDGTRLUIJKRY-UHFFFAOYSA-N 0.000 claims 1
- ZIQUETDGFJDUHB-UHFFFAOYSA-N 2-[[4-(3-ethylphenyl)-2-methylphenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound C(C)C=1C=C(C=CC=1)C1=CC(=C(C=C1)NC(=O)C1=C(CCC1)C(=O)O)C ZIQUETDGFJDUHB-UHFFFAOYSA-N 0.000 claims 1
- SKTMWKAOXLMYCW-UHFFFAOYSA-N 2-[[4-(3-methoxyphenyl)-2-methylphenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound COC=1C=C(C=CC=1)C1=CC(=C(C=C1)NC(=O)C1=C(CCC1)C(=O)O)C SKTMWKAOXLMYCW-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 206010025476 Malabsorption Diseases 0.000 claims 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- XPRDUGXOWVXZLL-UHFFFAOYSA-N 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3CCCC=3C(O)=O)=CC=2)=C1 XPRDUGXOWVXZLL-UHFFFAOYSA-N 0.000 abstract description 29
- 229950010644 vidofludimus Drugs 0.000 abstract description 29
- 230000002757 inflammatory effect Effects 0.000 abstract description 14
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 241000699670 Mus sp. Species 0.000 description 48
- 238000006243 chemical reaction Methods 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 42
- 230000015572 biosynthetic process Effects 0.000 description 40
- 238000003786 synthesis reaction Methods 0.000 description 38
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 26
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 25
- 239000007788 liquid Substances 0.000 description 25
- 238000004440 column chromatography Methods 0.000 description 24
- 229910052757 nitrogen Inorganic materials 0.000 description 22
- 230000001225 therapeutic effect Effects 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 19
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 18
- 239000003446 ligand Substances 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 16
- 238000000692 Student's t-test Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 238000010992 reflux Methods 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 11
- 239000003613 bile acid Substances 0.000 description 11
- 230000002440 hepatic effect Effects 0.000 description 11
- 229940116269 uric acid Drugs 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 206010067125 Liver injury Diseases 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- IKFBBRDUYDYTQG-UHFFFAOYSA-N (2,3,4,5-tetraphenylphenyl)phosphane Chemical compound Pc1cc(-c2ccccc2)c(-c2ccccc2)c(-c2ccccc2)c1-c1ccccc1 IKFBBRDUYDYTQG-UHFFFAOYSA-N 0.000 description 9
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 9
- 108010074051 C-Reactive Protein Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 229960003180 glutathione Drugs 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 230000002503 metabolic effect Effects 0.000 description 9
- 229910052763 palladium Inorganic materials 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 102100032752 C-reactive protein Human genes 0.000 description 8
- 229920003045 dextran sodium sulfate Polymers 0.000 description 8
- 206010003246 arthritis Diseases 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 101000870644 Homo sapiens Glutamate-cysteine ligase regulatory subunit Proteins 0.000 description 6
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 6
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 6
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000021588 free fatty acids Nutrition 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 102000006255 nuclear receptors Human genes 0.000 description 6
- 108020004017 nuclear receptors Proteins 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 5
- 102100033398 Glutamate-cysteine ligase regulatory subunit Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 101100390675 Mus musculus Fgf15 gene Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 102000023984 PPAR alpha Human genes 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 108020001756 ligand binding domains Proteins 0.000 description 5
- 230000006372 lipid accumulation Effects 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- INMZDDDQLHKGPF-UHFFFAOYSA-N 4-bromo-2-chloroaniline Chemical compound NC1=CC=C(Br)C=C1Cl INMZDDDQLHKGPF-UHFFFAOYSA-N 0.000 description 4
- 208000004232 Enteritis Diseases 0.000 description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010018634 Gouty Arthritis Diseases 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000003016 alphascreen Methods 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000014101 glucose homeostasis Effects 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 0 *C(C(CCC1)=C1C(Nc(c(*)c1)ccc1-c1cc(*)ccc1)=O)=O Chemical compound *C(C(CCC1)=C1C(Nc(c(*)c1)ccc1-c1cc(*)ccc1)=O)=O 0.000 description 2
- 206010048998 Acute phase reaction Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 238000008620 Cholesterol Assay Methods 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 2
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 2
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 2
- 101000930910 Homo sapiens Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 2
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 2
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 2
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 description 2
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004658 acute-phase response Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- KWSJBFAXOPFZSO-UHFFFAOYSA-L calcium 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylate Chemical class [Ca+2].COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3CCCC=3C([O-])=O)=CC=2)=C1.COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3CCCC=3C([O-])=O)=CC=2)=C1 KWSJBFAXOPFZSO-UHFFFAOYSA-L 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000008378 epithelial damage Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 238000013227 male C57BL/6J mice Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000010741 sumoylation Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- JIMVRUCDZGFJRE-UHFFFAOYSA-N (3-ethylphenyl)boronic acid Chemical compound CCC1=CC=CC(B(O)O)=C1 JIMVRUCDZGFJRE-UHFFFAOYSA-N 0.000 description 1
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 1
- QSWLFBMVIGQONC-UHFFFAOYSA-N (3-propan-2-ylphenyl)boronic acid Chemical compound CC(C)C1=CC=CC(B(O)O)=C1 QSWLFBMVIGQONC-UHFFFAOYSA-N 0.000 description 1
- JBDOSUUXMYMWQH-UHFFFAOYSA-N 1-naphthyl isothiocyanate Chemical compound C1=CC=C2C(N=C=S)=CC=CC2=C1 JBDOSUUXMYMWQH-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 101000747600 Mus musculus UDP-glucuronosyltransferase 1A9 Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 102100023172 Nuclear receptor subfamily 0 group B member 2 Human genes 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 102100039506 Organic solute transporter subunit alpha Human genes 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101000841641 Pleuronectes platessa UDP-glucuronosyltransferase Proteins 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091007630 SLC51A1 Proteins 0.000 description 1
- 101150043341 Socs3 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 238000008083 Urea Assay Methods 0.000 description 1
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical class C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 244000221110 common millet Species 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- PZBBESSUKAHBHD-UHFFFAOYSA-N methyl 2-oxocyclopentane-1-carboxylate Chemical compound COC(=O)C1CCCC1=O PZBBESSUKAHBHD-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 231100000748 severe hepatic injury Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000035903 transrepression Effects 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
Definitions
- the present invention relates to compounds, compositions and methods for treating diseases or conditions mediated by farnesoid X receptor (FXR) , and methods for the compound design and applications.
- FXR farnesoid X receptor
- Nuclear receptors represent a type of ligand-regulated transcription factors involved in a variety of biological processes.
- farnesoid X receptor FXR
- nuclear receptors such as FXR, play an important role in regulating virtually all aspects of human physiology including metabolism, inflammation, hepatic protection and regeneration, bile salt, fat and glucose homeostasis and other related physiological functions.
- FXR has become an excellent drug target for the treatment of many FXR-mediated diseases like cancer, aging, metabolic diseases such as high blood glucose, insulin resistance, hypertriglyceridemia, hypercholesterolemia, diabetes, obesity, biliary obstruction, gallstones, nonalcoholic fatty liver, atherosclerosis and other diseases (see, e.g., Fiorucci et al., (2010) Current Medicinal Chemistry, 17, 139-159 and Carotti et al., (2014) Current Topics in Medicinal Chemistry, 14, 2129-2142) .
- the coregulators include coactivators like the p160 factors that also referred to as the steroid receptor coactivators (SRC) family. Given the critical roles in human diseases, the ligands have been studied intensively in pharmaceutical development.
- SRC steroid receptor coactivators
- Cholestasis is composed of a variety of human liver diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, cystic fibrosis, and intrahepatic cholestasis of pregnancy (see, e.g., Pellicciari et al., (2002) Journal of medicinal chemistry 45, 3569-3572) .
- activation of FXR induces transcription of transporter genes involved in promoting bile acid clearance and represses genes involved in bile acid synthesis.
- the enterohepatic circulation of bile acids enables the absorption of fats and fat-soluble vitamins from the intestine and allows the elimination of cholesterol, toxins, and metabolic by-products such as bilirubin from the liver.
- FXR-null mice exhibit cholestatic liver disorder.
- the FXR activation resulted in reductions in inflammation, other markers of liver damage and increased expression of genes involved in bile acid transport (see e.g., Liu et al., (2003) Journal of Clinical Investigation 112, 1678-1687) .
- FXR agonists may be useful in the treatment of cholestatic liver diseases, such as cholestasis, liver inflammation, liver damage, primary sclerosing cholangitis, cystic fibrosis, and intrahepatic cholestasis of pregnancy.
- FXR modulators impact both bile acid synthesis and lipid metabolism, and are effective pharmaceutical agents in preventing and treating liver diseases associated with bile acid mediated cellular injury, fatty liver disease, liver cancer as well as atherosclerosis and cardiovascular disease. Moreover, studies on wide type and FXR -/- mice have determined that FXR plays pleotropic roles in regulating triglyceride, lipid, cholesterol, glucose metabolism in addition to bile acids homeostasis (see e.g., Sinal et al., (2000) Cell 102, 731-44) .
- Hypertriglycerides is a predictor of coronary heart disease risk factor, strategies targeting the hypertriglyceride are well prevention and treatment for coronary heart disease risk (see e.g., Cullen (2000) The American Journal of Cardiology 86, 943-949) . This is mainly attributed to the inverse relationship between serum triglycerides (TGs) and HDL cholesterol, since low levels of HDL increase the risk of vascular diseases.
- TGs serum triglycerides
- Bile acid lowers serum TGs, reduces SREBP-1c and lipogenic genes dependent on activating FXR and inducing the expression of SHP (see e.g., Lambert et al., (2003) The Journal of biological chemistry 278, 2563-2570 and Watanabe et al., (2004) The Journal of clinical investigation 113, 1408-1418) .
- FXR modulators can be used to treat or prevent the hypertriglyceride and the related coronary heart disease.
- FXR-null mice show features in glucose tolerance and insulin resistance (see e.g., Zhang et al., (2006) Proceedings of the National Academy of Sciences of the United States of America 103, 1006-1011) .
- FXR ligand Ivemectin was recently found to be specifically regulating glucose and cholesterol homeostasis dependent on FXR (see e.g., Jin et al., (2013) Nature communications 4, 1937) .
- FXR is a drug target in treating or preventing insulin resistance, hyperglycemia, hypercholesterol, obesity, diabetes as well as disorders related to glucose and cholesterol metabolism.
- FXR is an ideal target for nonalcoholic fatty liver disease (NAFLD) drug development due to its crucial roles in lipid metabolism (see e.g., Carr and Reid, (2015) Curr Atheroscler Rep 17, 500) .
- Activation of FXR reduced liver expression of genes involved in fatty acid synthesis, lipogenesis, and gluconeogenesis, as well as reducing the steatosis of obese rat (see e.g., Cipriani et al., (2010) J Lipid Res 51, 771-784) .
- FXR ligands Avermectin analogues are effective in regulating metabolic parameters tested, including reducing hepatic lipid accumulation, lowering serum cholesterol and glucose levels, and improving NAFLD in an FXR dependent manner (see e.g., Jin et al., (2015) Scientific reports 5, 17288) .
- FXR has been proposed as a target for improving non-alcoholic steatohepatitis (NASH) , or non-alcoholic fatty liver disease (NAFLD) from steatosis to cirrhosis, and even liver cancer.
- NASH non-alcoholic steatohepatitis
- NAFLD non-alcoholic fatty liver disease
- Hypercholesterolemia and dyslipidemia are important risk factors for cardiovascular disease (CVD) and atherosclerosis, characterized by elevated plasma triglycerides (TGs) and lowered HDL-cholesterol (HDL-C) , in combination with obesity, elevated blood glucose levels, and/or hypertension termed the metabolic syndrome (see e.g., Porez et al., (2012) J Lipid Res 53, 1723-1737) .
- CVD cardiovascular disease
- TGs plasma triglycerides
- HDL-C HDL-cholesterol
- FXR activation protects against atherosclerosis development as well as hyperlipidemia in ApoE -/- mice (see e.g., Hartman et al., (2009) J Lipid Res 50, 1090-1100 and Mencarelli et al., (2009) Am J Physiol Heart Circ Physiol 296, H272-281) .
- FXR ligands might be used in prevention and treatment of atherosclerosis and cardiovascular disease.
- FXR and its ligands are also involved in cellular inflammatory and immune responses (See e.g., Shaik F. B., et al., (2015) Inflamm Res 64 (1) : 9-20) .
- the regulation of FXR can negatively regulate various inflammatory factors such as tumor necrosis factor TNF ⁇ , IL-6, cycloxygenase (COX) -1, COX-2 etc., thereby inhibiting the occurrence and development of inflammation (see e.g., Gadaleta R. M., et al., Gut. 60 (4) : 463-72, 2011] .
- FXR modulators can inhibit the occurrence and development of inflammation by inducing cytokine signaling inhibitor repressors like SOCS3 (see e.g., Xu Z. Z., et al., Cellular Signaling 24: 1658-1664, 2012) .
- FXR deficiency is susceptible to gallbaldder inflammation and cholesterol gallstone disease (CGD) , indicating that FXR is a potential target in treating CGD (see e.g., Moschetta et al., (2004) Nature medicine 10, 1352-1358) .
- Emerging roles for FXR in the gut include protection against bacterial overgrowth and maintenance of intestinal barrier function.
- FXR activation protects against murine models of induced colitis (see e.g., Gadaleta et al., (2011) Gut 60, 463-472 and Vavassori et al., (2009) J Immunol 183, 6251-6261) . Theses suggest that FXR modulators can extenuate the damage of inflammation to various disorders, which can be useful as a therapeutic strategy for various inflammatory diseases.
- the inflammatory diseases include, but not limited to, rheumatoid arthritis (RA) , tendinitis or bursitis, fibromyalgia, muscular low back pain, chronic obstructive pulmonary disease (COPD) , psoriasis, pelvic inflammatory disease (PID) , asthma, pneumonia, polymyalgia rheumatica and gout.
- RA rheumatoid arthritis
- COPD chronic obstructive pulmonary disease
- PID pelvic inflammatory disease
- rheumatoid arthritis is an autoimmune disease affecting approximately 1%of the population worldwide.
- the monocytes/macrophages which are inflammatory cells, have been implicated in RA, leading to bone and cartilage destruction (see e.g., Wang Y., et al., Int Immunopharmacol. 2017; 50: 345-352) .
- TNF ⁇ is of major importance in rheumatoid arthritis (see e.g., Feldman M, et al., Annu Rev Immunol. 1996; 14: 397-440) .
- TNF ⁇ may serve as an indicator of activity in arthritis, including RA, OA and JIA.
- Overproduction of TNF ⁇ leads to autoimmune reactions, which may enhance the inflammatory and destructive process (see e.g., Hayer S, et al., J Immunol. 2005, 175 (12) : 8327-36) .
- CIA collagen-induced arthritis
- FXR may be a target for treating arthritis by inhibiting TNF ⁇ .
- FXR activation increased bile acid flux, which is a signal for liver regeneration in mice.
- FXR may promote homeostasis not only by regulating expression of appropriate metabolic target genes but also by driving homeotrophic liver growth (see e.g., Huang et al., (2006) Science 312, 233-6) .
- irregular regeneration of hepatocytes with cells over proliferation has been reported as an important factor in carcinogenesis (see e.g., Ueno et al., (2001) Hepatology 33, 357-362 and Wang et al., (2008) Hepatology 48, 1632-1643) .
- FXR -/- mice spontaneously developed liver tumors, while intestinal-selective FXR modulators activation is sufficient to prevent hepatic malignancy (see, e.g., Yang et al., (2007) Cancer Res 67, 863-867 and Degirolamo et al., (2015) Hepatology 61: 161-70) .
- FXR deficiency in the intestine promotes Wnt signaling with expansion of the basal proliferative compartment, while FXR activation can induce the apoptosis of colon cancer cells (see e.g., Modica et al., (2008) Cancer Res 68, 9589-9594) .
- FXR can be a target to protect against carcinogenesis such as liver and intestinal cancer.
- FXR also plays a critical role in aging-induced fatty liver (see e.g., Xiong et al., (2014) J Hepatol. 60 (4) : 847-54) , and expression and activity of FXR are increased in the livers of the long-lived Little mice, both suggesting an association between FXR and aging (see e.g., Jiang et al., (2013) Mech Ageing Dev. 134 (9) : 407-15) . Activation of FXR is able to alleviate age-related liver regeneration defects (see e.g., Chen et al., (2010) Hepatology 51 (3) : 953-62) . These findings highlight FXR as a potential target of drug design for disorders related to aging such as liver regeneration and extension of chronological lifespan.
- FXR FXR ligands
- the regulation of FXR by ligands has beneficial effects on bone metabolism through modulating bone formation, differentiation and resorption, resulting in preventing bone loss and enhancing bone mass gain (see e.g., Cho et al., (2013) J Bone Miner Res. 28 (10) : 2109-21) , suggesting therapeutic roles of FXR ligands in treating disorders related to bone formation such as osteoporosis, bone hyperplasia and osteoarthritis.
- the present application relates to compounds, or pharmaceutically acceptable salt, isomers, or prodrugs thereof, that bind to the farnesoid X receptor (FXR) , for the treatment of FXR-mediated diseases or conditions, including but not limited to inflammation, analgesia, cholestasis, colitis, chronic liver diseases, gastrointestinal diseases, renal diseases, cardiovascular disease, kidney disease, inflammatory disorder, metabolic diseases and various cancers.
- FXR farnesoid X receptor
- Another aspect of this invention is directed to methods of treating, preventing, inhibiting, or ameliorating the symptoms of a disease or disorder or a condition that is modulated by FXR activity, by administering to the mammal a therapeutically effective amount of at least one compound or combinations of compounds disclosed herein.
- FXR ligand refers to any compounds that regulate FXR activity as full agonists, partial agonists, antagonists, inverse agonists, or selective nuclear receptor modulators, due to their diverse characteristics in FXR binding mode, regulating transcription and post-translational modification and their ability in inducing FXR to recruit various co-regulators.
- Post-translational modifications such as SUMOylation and phosphorylation, are also differentially associated with transactivation or transrepression, respectively.
- FXR activity refers any FXR activities relating to therapeutic effects on human disease.
- FXR activity regulated by compounds for use in accordance with the present invention include, but is not limited to, transcriptional activity, phosphorylation, acetylation, methylation, ubiquitination, sumoylation, any other posttranscriptional activity, any other protein modification, and protein-protein interactions relating to signal transduction.
- compositions of this invention may comprise the compounds described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Such compositions may optionally comprise an additional therapeutic agent.
- EC50 refers to a dosage, concentration or amount of a said compound which induces a response halfway between the baseline and maximum after a specified exposure time, commonly used as a measure of drug's potency.
- Figure 1 The structure of vidofludimus bound with FXR LBD in cartoon representation (A) .
- FIG. 1 H&E stained liver sections from compounds pretreated mice with APAP-induced liver injury.
- FIG. 1 The H&E staining (A) and Oil Red O staining (B) of liver sections from ob/ob mice treated with 10 mg/kg of compounds for 10 days.
- FIG. 4 The H&E staining (A) and Oil Red O staining (B) of liver sections from db/db mice treated with 10 mg/kg of compounds for 10 days.
- FIG. 1 H&E stained colonic sections from compounds pretreated mice with DSS-induced colitis.
- Example 1 Vidofludimus is a FXR ligand.
- FXR ligand binding domain (LBD) as a bait to screen chemical libraries based on AlphaScreen biochemical assay, which determines the efficacy of small molecules in influencing binding affinity of FXR with coregulator peptides (see e.g., Jin et al., (2013) Nature communications 4, 1937) .
- Results from a clinical compounds library revealed vidofludimus (synonyms: 4sc-101; SC12267) potently promoted the interaction of FXR with coactivator LXXLL motifs from SRC1-2 and SRC2-3 (Table 1) , indicating this compound is able to regulate FXR activity.
- Example 2 Compounds modulate FXR activity.
- vidofludimus Based on the structure-activity-relationship of vidofludimus and FXR, we have designed and synthesized series of vidofludimus analogues targeting FXR (Table 2) .
- the compounds that modulate FXR activity are shown in Table 1.
- the in vivo upregulated FXR target genes such as OST ⁇ , GCLM and UGT1A1 (Lee et al., Mol Endocrinol 2010, 24 (8) : 1626–1636) in liver (Table 3) , and FGF15 (Inagaki et al., Cell Metab. 2005 Oct; 2 (4) : 217-25) in intestine (Table 9 and Table 20) further confirmed that these compounds are physiologically functional FXR ligands.
- Example 3 Therapeutic effects of compounds on liver injury.
- Acetaminophen (APAP) -induced liver injury in mouse is a commonly used model to study drugs in protecting liver.
- Overdose of APAP causes liver injury by inducing the production of reactive oxygen species and reactive nitrogen species, and excessive consumption of reductive substances such as antioxidant glutathione (GSH) , leading to the reduction of GSH in vivo, and the following upregulation of the activities of the aspartate aminotransferase (AST) the alanine aminotransferase (ALT) , the alkaline phosphatase (ALP) and the lactate dehydrogenase (LDH) , which will result in liver inflammation and necrosis.
- GSH antioxidant glutathione
- AST aspartate aminotransferase
- ALT alanine aminotransferase
- ALP alkaline phosphatase
- LDH lactate dehydrogenase
- vidofludimus We selected vidofludimus, vidofludimus sodium salt and vidofludimus calcium salt to test the hepatoprotective effects of our compounds.
- Compounds were solved with DMSO and then prepared to work concentration with 40%HBC (2-hydroxypropyl- ⁇ -cyclodextrin) in which the final work concentrations of compounds are 10 mg/kg body weight in 200 ⁇ l injection volume and the concentration of DMSO is 10%.
- Compounds were intraperitoneal (i.p. ) injected once daily for five days. Six hours after the fifth injection, 500 mg/kg body weight of APAP solved in PBS was i.p. injected to the mice. 24 hours later, mice were sacrificed.
- liver histology characterization was analyzed by haematoxylin and eosin (H&E) staining with paraffin-embedded sections by standard procedures.
- Other liver tissues were collected for detecting the reduced GSH levels using Reduced Glutathione Kit (Nanjing Jiancheng Bioengineering Institute, China) , and the mRNA expression of genes involved in liver repairing, such as GCLM and UGT1a1, by RT-PCR.
- GCLM is the gene encoding the modifier subunit of the glutamate cysteine ligase GCLM, which is the rate-limiting enzyme in GSH biosynthesis.
- UGT1a1 is a uridine diphosphate glucuronosyltransferase (UDP-glucuronosyltransferase, UDPGT) , an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. Mutations in this gene cause serious problems for bilirubin metabolism.
- the serums were collected to measure enzymes activities including AST, ALT, ALP and LDH using kits from Nanjing Jiancheng Bioengineering Institute, China.
- RNA was isolated using Tissue RNA kit (Omega Bio-Tek, GA) .
- the first strand cDNA was obtained by TAKARA reverse transcription kit.
- RT-qPCR was performed on a CFX96 TM Real-Time PCR Detection System (Bio-Rad) using SYBR Premix Ex TaqTM (TAKARA) . Relative mRNA expression levels were normalized to GAPDH levels.
- Results As shown in Figure 2, the pathological sections in control group displayed obvious cell infiltration, vacuolization and necrosis in hepatic lobule. There were a large number of inflammatory cell infiltration, cell turbidity, dissolved karyopycnosis or broken in lobules and portal area. And liver cell cords were also blurred. Compared to the severe liver injury in the control group, pre-treated with vidofludimus, vidofludimus sodium salt and vidofludimus calcium salt obviously protected liver from injury.
- Soluble oligomeric amyloid beta (A ⁇ ) species are now considered to be of major pathological importance in Alzheimer's disease (AD) .
- a ⁇ -induced oxidative stress can be due to either an increase in ROS or a decrease in endogenous antioxidants like GSH and the activities of antioxidant enzymes. Up-regulation of reduced GSH may be protective against the oxidative and neurotoxic effects of oligomeric A ⁇ .
- vidofludimus treatment efficaciously increased the level of GSH by upregulating the expression of GCLM, indicating the potential therapeutic roles of our compounds in treating AD.
- Example 4 Effects of compounds on metaboli diseases mouse model.
- mice were fed with high-fat diet (HFD, Research Diets, D12492) and treated with either vehicle (40%HBC) or compounds (10 mg/kg body weight) dissolved in vehicle by intra-peritoneally (i.p. ) injection once a day for 10 days.
- HFD high-fat diet
- vehicle 40%HBC
- compounds 10 mg/kg body weight
- mice were fasted for 6 hours with free access to water, and then sacrificed.
- Part of each liver was fixed in 4%paraformaldehyde for haematoxylin and eosin (H&E) staining; part of each liver was frozen for oil red O staining, and other liver tissues were stored in liquid nitrogen for triglyceride and cholesterol measurement using Triglyceride Assay Kit and Cholesterol Assay Kit (Applygen, Beijing, China; Nanjing Jiancheng Bioengineering Institute, China) .
- Liver histology characterization was analyzed through H&E staining with paraffin-embedded sections by standard procedures.
- the serum levels of uric acid (UA) and ALP were measured with kits from Nanjing Jiancheng Bioengineering Institute; the mouse high sensitivity c-reactive protein, hs-crp ELISA KIT (BioLab, Beijing, China) was used to measure the serum CRP level, and the Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem., USA) was used to measure the serum insulin level.
- liver from mice treated with compounds displayed obvious difference in pathology.
- Table 4 and Table 5 the liver/body weight ratios were significantly decreased in compounds treated ob/ob and db/db mice.
- the hepatic triglyceride and cholesterol levels were all significantly decreased in compounds treated mice.
- Figure 3A and Figure 4A the histological examination of liver sections obtained from vehicle treated mice showed the extensive existence of vesicular hepatocyte vacuolation, while compounds treatment efficaciously reversed the liver from hepatic steatosis in db/db mice with disappeared hepatic lipid accumulation and showed tight compact structure of the liver cells.
- liver sections from oil red O staining further confirmed the therapeutic effects of compounds on hepatic lipid accumulation.
- liver sections from vehicle treated mice showed abundant lipid accumulation, especially containing many large lipid droplets, while liver sections from mice treated with compounds dramatically reduced the lipid accumulation.
- Patients suffering from non-alcoholic fatty liver disease (NAFLD) display a variety of hepatic dysfunctions, ranging from abnormal triglyceride accumulation in hepatocytes (steatosis) to steatohepatitis (non-alcoholic steatohepatitis, NASH) with fibrosis.
- NASH non-alcoholic steatohepatitis
- Table 7 The compounds regulated mRNA levels of genes related to metabolism in liver of HFD-fed ob/ob mice.
- the serum cholesterol levels were significantly lowered in compounds treated ob/ob and db/db mice (Table 4, Table 5 &Table 6, indicating the therapeutic effects of the compounds on hypercholesterolemia.
- the serum triglyceride levels were significantly lowered in compounds treated ob/ob mice (Table 4 and Table 6) , indicating the therapeutic effects of the compounds on hypertriglyceridemia.
- the serum glucose levels were significantly lowered in compounds treated mice (Table 5 and Table 6) , indicating the therapeutic effects of our compounds on hyperglycemia and diabetes.
- High levels of blood triglycerides and glucose are the alert indicators of cardiovascular disease. These indicators reflect the high risk for development of cardiovascular disease.
- the compounds treatment significantly decreased the blood levels of glucose and triglyceride, indicating their therapeutic effects on cardiovascular diseases.
- PPAR ⁇ controls lipid flux in the liver by modulating FA transport and ⁇ -oxidation, and improves plasma lipid profiles by decreasing triglyceride (TG) levels and increasing high-density lipoprotein cholesterol levels.
- PPAR ⁇ activation inhibits inflammatory genes induced by NF- ⁇ B, and decreases the expression of acute-phase response genes. Accordingly, PPAR ⁇ deficiency increases susceptibility to NAFLD, NASH, hepatic inflammation and acute phase responses (see e.g., Ip E., et al., (2003) Hepatology; 38: 123–132) .
- Table 8 The treatment of compounds regulated mRNA levels of collagens in liver.
- NAFLD with excessive fat accumulation in liver will affect the blood and oxygen supplies to liver and the metabolism of liver organ, resulting in amounts of cell swelling, inflammatory infiltration and necrosis in liver. Once fibrosis and false lobules appear, cirrhosis will happen and the risk of liver cancer will be greatly increased.
- the levels of various collagen contents are higher in patients with liver cirrhosis. As shown in Table 8, the compounds decreased the mRNA levels of ⁇ 1 (I) collagen and ⁇ 2 (I) collagen, suggesting their effects in preventing NAFLD and cirrhosis.
- Table 9 The treatment of compounds regulated FXR target genes and inflammatory genes.
- FGF15 plays an important role in feedback inhibition of hepatic bile acid synthesis.
- FXR directly binds to the response element of the promoter of FGF15 and regulates its expression.
- Table 9 the synthetic compounds increased the mRNA levels of FGF15, and efficaciously lowered the mRNA levels of inflammatory genes in both liver and intestine tissues, indicating their therapeutic effects on hepatitis and enteritis.
- C-reactive protein is synthesized by the liver in response to factors released by macrophages and fat cells (adipocytes) (see e.g. Lau DC et al., (2005) Am J Physiol Heart Circ Physiol. 288: H2031–41. ) . Elevated levels of CRP are commonly found in gouty arthritis. As shown in Table 4 &10, our compounds decreased the serum level of UA and CRP, indicating the potential therapeutic effects of these compounds in treating gout and gouty arthritis.
- BUN blood urea nitrogen
- the BUN levels were measured with the Urea Assay kit (Nanjing Jiancheng Bioengineering Institute, China) in this example, and the results showed that the compounds decreased the BUN levels in HFD-fed ob/ob mice (Table 4, 5 &12) , suggesting the therapeutic effects of our compounds on various kidney diseases including glomerulonephritis, interstitial nephritis, acute and chronic renal failure, renal lesions, renal destructive lesions and uremia that have increased BUN.
- Example 5 Effects of compounds on ob/ob mice administrated by oral gavage.
- n 1-3 per group.
- mice The levels of the serum FFA (Table 14) , triglycerides (Table 15) , UA (Table 16) and the hepatic level of total cholesterol (Table 17) of mice were reduced in the compounds treated mice, and the mRNA expression levels of inflammatory factors (Table 18) in liver tissues were down-regulated in the compounds treated mice.
- these data suggest that our compounds are potential drug candidates for treating diseases such as fatty liver diseases, hypertriglyceridemia, hepatitis, gout and gouty arthritis. This example also indicates that orally administrated with our compounds are also efficacious in treating metabolic diseases.
- Compound FFA (mM) Compound FFA (mM) Vehicle 1.94 ⁇ 0.06 FD12 1.72 ⁇ 0.08 a FD4 1.22 FD13 1.63 ⁇ 0.06 b FD6 1.17 FD20 1.35 ⁇ 0.26 a
- n 1-3 per group.
- Table 17 The effects of compounds on the level of hepatic cholesterol.
- Table 18 The effects of compounds on the mRNA levels of inflammatory factors in liver tissues.
- Compound ⁇ -SMA IL-1 ⁇ Compound ⁇ -SMA IL-1 ⁇ Vehicle 1.06 ⁇ 0.21 1.00 ⁇ 0.25 FD12 0.35 ⁇ 0.16 a 0.48 ⁇ 0.27 FD4 0.37 0.77 FD13 0.38 ⁇ 0.21 a 0.57 ⁇ 0.23 FD6 0.42 0.49 FD20 0.60 ⁇ 0.25 0.46 ⁇ 0.19 a FD9 0.54 ⁇ 0.34 0.38 ⁇ 0.19 a FD29 0.32 ⁇ 0.19 a 0.55 ⁇ 0.23 a FD10 0.27 0.46 ⁇ 0.21 FD31 0.34 ⁇ 0.19 a 0.66 ⁇ 0.17 FD11 0.42 ⁇ 0.18 a 0.38 ⁇ 0.16 a Vidofludimus 0.32 ⁇ 0.22 a 0.53 ⁇ 0.24
- DSS Dextran sodium sulfate
- CMC-Na carboxymethycellulose
- Inflammatory cytokines are produced during inflammation, and thus are markers of the inflammatory reaction.
- compounds treatment decreased the inflammatory cytokines levels in DSS-induced colitis models, demonstrating the therapeutic effects of compounds in treating enteritis.
- Table 20 Compounds regulated mRNA expression of FXR target gene and inflammatory factors.
- TNF ⁇ secreted from the macrophages has becoming an indicator of activity in arthritis and a target for treating arthritis.
- 8-week-old male C57BL/6J mice were injected with sterile thioglycolic acid broth into the peritoneum.
- mice were sacrificed and injected with 10 mL of RPMI-1640 medium containing 5%FBS into the peritoneum to harvest peritoneal macrophages. Collected cells were centrifuged at 160 ⁇ g for 5 min, and the cell pellet was washed with PBS and centrifuged again.
- the cell pellet was then suspended in RPMI-1640 medium supplemented with 100 U/mL of penicillin, 100 ⁇ g/mL of streptomycin and 10%FBS, and plated into 12-well plates. After incubation at 37 °C for 3 h, the cells were washed with PBS three times to remove unattached cells such as neutrophils, and then cultured in the same RPMI-1640 medium. 24 h after the cells were plated into the wells, 10 uM of compounds were added into the culture medium. Additional 2 h later, 0.5 ug/mL of LPS were added into the culture medium, and cells were harvested in 22 h. The media were collected and the secreted TNF ⁇ in the medium were detected using the Mouse TNF ⁇ ELISA kit (NeoBioscience) .
- Table 21 Compounds suppressed the production of TNF ⁇ in LPS-induced macrophages.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compounds such as vidofludimus and its analogues useful in modulating the activity of nuclear receptor FXR. Also disclosed are the methods for treating FXR-mediated disease or process in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound claimed, wherein the FXR-mediated disease or condition linked to chronic liver diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, inflammatory diisease such as rheumatoid arthritis and inflammatory bowel disease, cardiovascular diseases, or metabolic diseases such as diabetes and obesity.
Description
CROSS-REFERENCE TO RELATED APPLICATION
This application claims priority to, and the benefit of, China patent application 201710192430.1, filed on March 28, 2017, the disclosures of which are incorporated herein by reference.
The present invention relates to compounds, compositions and methods for treating diseases or conditions mediated by farnesoid X receptor (FXR) , and methods for the compound design and applications.
Nuclear receptors represent a type of ligand-regulated transcription factors involved in a variety of biological processes. For example, farnesoid X receptor (FXR) , highly expressed in mammalian liver, intestine, kidney and adrenal gland, is one of the 48 known human nuclear receptors. Nuclear receptors, such as FXR, play an important role in regulating virtually all aspects of human physiology including metabolism, inflammation, hepatic protection and regeneration, bile salt, fat and glucose homeostasis and other related physiological functions. As such, FXR has become an excellent drug target for the treatment of many FXR-mediated diseases like cancer, aging, metabolic diseases such as high blood glucose, insulin resistance, hypertriglyceridemia, hypercholesterolemia, diabetes, obesity, biliary obstruction, gallstones, nonalcoholic fatty liver, atherosclerosis and other diseases (see, e.g., Fiorucci et al., (2010) Current Medicinal Chemistry, 17, 139-159 and Carotti et al., (2014) Current Topics in Medicinal Chemistry, 14, 2129-2142) .
Small molecules known as ligands play important roles in modulating the activity of nuclear receptors, since the binding of ligands can determine the recruitment of coregulators. The coregulators include coactivators like the p160 factors that also referred to as the steroid receptor coactivators (SRC) family. Given the critical roles in human diseases, the ligands have been studied intensively in pharmaceutical development.
Cholestasis is composed of a variety of human liver diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, cystic fibrosis, and intrahepatic cholestasis of pregnancy (see, e.g., Pellicciari et al., (2002) Journal of medicinal chemistry 45, 3569-3572) . In the liver, activation of FXR induces transcription of transporter genes involved in promoting bile acid clearance and represses genes involved in bile acid synthesis. The enterohepatic circulation of bile acids enables the absorption of fats and fat-soluble vitamins from the intestine and allows the elimination of cholesterol, toxins, and metabolic by-products such as bilirubin from the liver. FXR-null mice exhibit cholestatic liver disorder. In the bile duct-ligation and α-naphthylisothiocyanate models of cholestasis, the FXR activation resulted in reductions in inflammation, other markers of liver damage and increased expression of genes involved in bile acid transport (see e.g., Liu et al., (2003) Journal of Clinical Investigation 112, 1678-1687) . These suggest therapeutic applications of FXR ligands can been used to treat liver disorders associated with cholestasis. FXR agonists may be useful in the treatment of cholestatic liver diseases, such as cholestasis, liver inflammation, liver damage, primary sclerosing cholangitis, cystic fibrosis, and intrahepatic cholestasis of pregnancy.
FXR modulators impact both bile acid synthesis and lipid metabolism, and are effective pharmaceutical agents in preventing and treating liver diseases associated with bile acid mediated cellular injury, fatty liver disease, liver cancer as well as atherosclerosis and cardiovascular disease. Moreover, studies on wide type and FXR
-/- mice have determined that FXR plays pleotropic roles in regulating triglyceride, lipid, cholesterol, glucose metabolism in addition to bile acids homeostasis (see e.g., Sinal et al., (2000) Cell 102, 731-44) . Hypertriglycerides is a predictor of coronary heart disease risk factor, strategies targeting the hypertriglyceride are well prevention and treatment for coronary heart disease risk (see e.g., Cullen (2000) The American Journal of Cardiology 86, 943-949) . This is mainly attributed to the inverse relationship between serum triglycerides (TGs) and HDL cholesterol, since low levels of HDL increase the risk of vascular diseases. Bile acid lowers serum TGs, reduces SREBP-1c and lipogenic genes dependent on activating FXR and inducing the expression of SHP (see e.g., Lambert et al., (2003) The Journal of biological chemistry 278, 2563-2570 and Watanabe et al., (2004) The Journal of clinical investigation 113, 1408-1418) . As such, FXR modulators can be used to treat or prevent the hypertriglyceride and the related coronary heart disease.
FXR-null mice show features in glucose tolerance and insulin resistance (see e.g., Zhang et al., (2006) Proceedings of the National Academy of Sciences of the United States of America 103, 1006-1011) . In addition to GW4064, FXR ligand Ivemectin was recently found to be specifically regulating glucose and cholesterol homeostasis dependent on FXR (see e.g., Jin et al., (2013) Nature communications 4, 1937) . As such, FXR is a drug target in treating or preventing insulin resistance, hyperglycemia, hypercholesterol, obesity, diabetes as well as disorders related to glucose and cholesterol metabolism.
FXR is an ideal target for nonalcoholic fatty liver disease (NAFLD) drug development due to its crucial roles in lipid metabolism (see e.g., Carr and Reid, (2015) Curr Atheroscler Rep 17, 500) . Activation of FXR reduced liver expression of genes involved in fatty acid synthesis, lipogenesis, and gluconeogenesis, as well as reducing the steatosis of obese rat (see e.g., Cipriani et al., (2010) J Lipid Res 51, 771-784) . FXR ligands Avermectin analogues are effective in regulating metabolic parameters tested, including reducing hepatic lipid accumulation, lowering serum cholesterol and glucose levels, and improving NAFLD in an FXR dependent manner (see e.g., Jin et al., (2015) Scientific reports 5, 17288) . Taken together, FXR has been proposed as a target for improving non-alcoholic steatohepatitis (NASH) , or non-alcoholic fatty liver disease (NAFLD) from steatosis to cirrhosis, and even liver cancer.
Hypercholesterolemia and dyslipidemia are important risk factors for cardiovascular disease (CVD) and atherosclerosis, characterized by elevated plasma triglycerides (TGs) and lowered HDL-cholesterol (HDL-C) , in combination with obesity, elevated blood glucose levels, and/or hypertension termed the metabolic syndrome (see e.g., Porez et al., (2012) J Lipid Res 53, 1723-1737) . FXR activation protects against atherosclerosis development as well as hyperlipidemia in ApoE
-/- mice (see e.g., Hartman et al., (2009) J Lipid Res 50, 1090-1100 and Mencarelli et al., (2009) Am J Physiol Heart Circ Physiol 296, H272-281) . Thus, FXR ligands might be used in prevention and treatment of atherosclerosis and cardiovascular disease.
FXR and its ligands are also involved in cellular inflammatory and immune responses (See e.g., Shaik F. B., et al., (2015) Inflamm Res 64 (1) : 9-20) . The regulation of FXR can negatively regulate various inflammatory factors such as tumor necrosis factor TNFα, IL-6, cycloxygenase (COX) -1, COX-2 etc., thereby inhibiting the occurrence and development of inflammation (see e.g., Gadaleta R. M., et al., Gut. 60 (4) : 463-72, 2011] . Meanwhile, FXR modulators can inhibit the occurrence and development of inflammation by inducing cytokine signaling inhibitor repressors like SOCS3 (see e.g., Xu Z. Z., et al., Cellular Signaling 24: 1658-1664, 2012) . FXR deficiency is susceptible to gallbaldder inflammation and cholesterol gallstone disease (CGD) , indicating that FXR is a potential target in treating CGD (see e.g., Moschetta et al., (2004) Nature medicine 10, 1352-1358) . Emerging roles for FXR in the gut include protection against bacterial overgrowth and maintenance of intestinal barrier function. FXR activation protects against murine models of induced colitis (see e.g., Gadaleta et al., (2011) Gut 60, 463-472 and Vavassori et al., (2009) J Immunol 183, 6251-6261) . Theses suggest that FXR modulators can extenuate the damage of inflammation to various disorders, which can be useful as a therapeutic strategy for various inflammatory diseases. The inflammatory diseases include, but not limited to, rheumatoid arthritis (RA) , tendinitis or bursitis, fibromyalgia, muscular low back pain, chronic obstructive pulmonary disease (COPD) , psoriasis, pelvic inflammatory disease (PID) , asthma, pneumonia, polymyalgia rheumatica and gout.
For example, rheumatoid arthritis (RA) is an autoimmune disease affecting approximately 1%of the population worldwide. The monocytes/macrophages, which are inflammatory cells, have been implicated in RA, leading to bone and cartilage destruction (see e.g., Wang Y., et al., Int Immunopharmacol. 2017; 50: 345-352) . Among the released cytokines, TNFα is of major importance in rheumatoid arthritis (see e.g., Feldman M, et al., Annu Rev Immunol. 1996; 14: 397-440) . It has been reported that the levels of TNFα in serum and synovial fluid were significantly higher in RA and osteoarthritis arthritis (OA) patients than that in the normal group (see e.g., Guan X., et al., Qingdao Med J 2008, 40 (1) : 9-12; Sun B., et al., Journal of Radioimmunology 2000, 13 (3) : 169) . Also, the serum level of TNFα is reported significantly higher in patients with active Juvenile Idiopathic Arthritis (JIA) (see e.g., Shen H., et al., Chines e J Trad M ed T raum &Orthop 2007, 15 (9) : 3-5) . These results suggest that TNFα may serve as an indicator of activity in arthritis, including RA, OA and JIA. Overproduction of TNFα leads to autoimmune reactions, which may enhance the inflammatory and destructive process (see e.g., Hayer S, et al., J Immunol. 2005, 175 (12) : 8327-36) . Several groups have shown that collagen-induced arthritis (CIA) in mice may be treated effectively with anti-TNFα antibody or other TNFα inhibitors (see e.g., MaY and Pope RM. Curr Pharm Des, 2005, 11 (5) : 5695-80) . These reports suggest that FXR may be a target for treating arthritis by inhibiting TNFα.
FXR activation increased bile acid flux, which is a signal for liver regeneration in mice. FXR may promote homeostasis not only by regulating expression of appropriate metabolic target genes but also by driving homeotrophic liver growth (see e.g., Huang et al., (2006) Science 312, 233-6) . However, irregular regeneration of hepatocytes with cells over proliferation has been reported as an important factor in carcinogenesis (see e.g., Ueno et al., (2001) Hepatology 33, 357-362 and Wang et al., (2008) Hepatology 48, 1632-1643) . FXR
-/- mice spontaneously developed liver tumors, while intestinal-selective FXR modulators activation is sufficient to prevent hepatic malignancy (see, e.g., Yang et al., (2007) Cancer Res 67, 863-867 and Degirolamo et al., (2015) Hepatology 61: 161-70) . FXR deficiency in the intestine promotes Wnt signaling with expansion of the basal proliferative compartment, while FXR activation can induce the apoptosis of colon cancer cells (see e.g., Modica et al., (2008) Cancer Res 68, 9589-9594) . Taken together, FXR can be a target to protect against carcinogenesis such as liver and intestinal cancer.
FXR also plays a critical role in aging-induced fatty liver (see e.g., Xiong et al., (2014) J Hepatol. 60 (4) : 847-54) , and expression and activity of FXR are increased in the livers of the long-lived Little mice, both suggesting an association between FXR and aging (see e.g., Jiang et al., (2013) Mech Ageing Dev. 134 (9) : 407-15) . Activation of FXR is able to alleviate age-related liver regeneration defects (see e.g., Chen et al., (2010) Hepatology 51 (3) : 953-62) . These findings highlight FXR as a potential target of drug design for disorders related to aging such as liver regeneration and extension of chronological lifespan.
The regulation of FXR by ligands has beneficial effects on bone metabolism through modulating bone formation, differentiation and resorption, resulting in preventing bone loss and enhancing bone mass gain (see e.g., Cho et al., (2013) J Bone Miner Res. 28 (10) : 2109-21) , suggesting therapeutic roles of FXR ligands in treating disorders related to bone formation such as osteoporosis, bone hyperplasia and osteoarthritis.
Many FXR ligands have been described, but have limitations owing to side effects and uncertain bioavailabilities (see e.g., Watanabe et al., (2011) The Journal of biological chemistry 286, 26913-26920) . Accordingly, there is a need for compositions, compounds, and systems to treat FXR-mediated diseases.
SUMMARY OF THE INVENTION
The present application relates to compounds, or pharmaceutically acceptable salt, isomers, or prodrugs thereof, that bind to the farnesoid X receptor (FXR) , for the treatment of FXR-mediated diseases or conditions, including but not limited to inflammation, analgesia, cholestasis, colitis, chronic liver diseases, gastrointestinal diseases, renal diseases, cardiovascular disease, kidney disease, inflammatory disorder, metabolic diseases and various cancers.
Another aspect of this invention is directed to methods of treating, preventing, inhibiting, or ameliorating the symptoms of a disease or disorder or a condition that is modulated by FXR activity, by administering to the mammal a therapeutically effective amount of at least one compound or combinations of compounds disclosed herein.
As used herein, the term “FXR ligand” refers to any compounds that regulate FXR activity as full agonists, partial agonists, antagonists, inverse agonists, or selective nuclear receptor modulators, due to their diverse characteristics in FXR binding mode, regulating transcription and post-translational modification and their ability in inducing FXR to recruit various co-regulators. Post-translational modifications, such as SUMOylation and phosphorylation, are also differentially associated with transactivation or transrepression, respectively.
As used herein, the term “FXR activity” refers any FXR activities relating to therapeutic effects on human disease. For example, FXR activity regulated by compounds for use in accordance with the present invention include, but is not limited to, transcriptional activity, phosphorylation, acetylation, methylation, ubiquitination, sumoylation, any other posttranscriptional activity, any other protein modification, and protein-protein interactions relating to signal transduction.
In some embodiments, the compounds for use in the methods described herein may be formulated as a therapeutically effective amount of pharmaceutical compositions. Pharmaceutical compositions of this invention may comprise the compounds described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Such compositions may optionally comprise an additional therapeutic agent.
As used herein, “EC50” refers to a dosage, concentration or amount of a said compound which induces a response halfway between the baseline and maximum after a specified exposure time, commonly used as a measure of drug's potency.
The technology used herein, is also described in Jin et al., (2013) Nature communications 4, 1937 and Jin et al., (2015) Scientific reports 5, 17288.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1. The structure of vidofludimus bound with FXR LBD in cartoon representation (A) . 2Fo-Fc electron density map (1.0σ) showing the bound vidofludimus and the surrounding FXR residues (B) .
Figure 2. H&E stained liver sections from compounds pretreated mice with APAP-induced liver injury.
Figure 3. The H&E staining (A) and Oil Red O staining (B) of liver sections from ob/ob mice treated with 10 mg/kg of compounds for 10 days.
Figure 4. The H&E staining (A) and Oil Red O staining (B) of liver sections from db/db mice treated with 10 mg/kg of compounds for 10 days.
Figure 5. H&E stained colonic sections from compounds pretreated mice with DSS-induced colitis.
EXAMPLES
The following specific examples:
Example 1. Vidofludimus is a FXR ligand.
In search of novel ligands for FXR, we used FXR ligand binding domain (LBD) as a bait to screen chemical libraries based on AlphaScreen biochemical assay, which determines the efficacy of small molecules in influencing binding affinity of FXR with coregulator peptides (see e.g., Jin et al., (2013) Nature communications 4, 1937) . Results from a clinical compounds library revealed vidofludimus (synonyms: 4sc-101; SC12267) potently promoted the interaction of FXR with coactivator LXXLL motifs from SRC1-2 and SRC2-3 (Table 1) , indicating this compound is able to regulate FXR activity. To unravel the molecular basis for the recognition of FXR by vidofludimus, we performed structural studies on the FXR LBD complexed with vidofludimus. The AlphaScreen and crystallization of FXR LBD protein were performed as described previously (see e.g., Jin et al., (2013) Nature communications 4, 1937) . The structure reveals that the vidofludimus-bound FXR LBD resembles most agonist-bound nuclear receptor structures (Figure 1A) . The existence of vidofludimus was apparent from the highly revealing electron density map shown in Figure 1B.
Example 2. Compounds modulate FXR activity.
Based on the structure-activity-relationship of vidofludimus and FXR, we have designed and synthesized series of vidofludimus analogues targeting FXR (Table 2) . The compounds that modulate FXR activity are shown in Table 1. The in vivo upregulated FXR target genes, such as OSTα, GCLM and UGT1A1 (Lee et al., Mol Endocrinol 2010, 24 (8) : 1626–1636) in liver (Table 3) , and FGF15 (Inagaki et al., Cell Metab. 2005 Oct; 2 (4) : 217-25) in intestine (Table 9 and Table 20) further confirmed that these compounds are physiologically functional FXR ligands.
Table 1. Potency of compounds in regulating FXR activity as determined by the ability in inducing FXR to recruit coactivator motifs by AlphaScreen assay. The indicated values are fold changes by 5 μM compounds.
Example 2. Preparation of compounds.
The following examples illustrate synthetic routes of compounds listed in Table 3.
1. Synthesis of Intermediates M1 and M2
1) Synthesis of M1
80 mL of dichloromethane was added into 2.85 g (20 mmol) of methyl 2-oxocyclopentanecarboxylate, and the reaction was cooled to -78℃. Then, 17 mL of N, N-diisopropyl was added to the reaction, and continuously stirred for 15 min. After trifluoromethanesulfonic anhydride (2.5 mL, 24.0 mmol) was added dropwise for about 30 min, the reaction was warmed to room temperature and allowed to react overnight. Then, the reaction was cooled to 0℃, and was quenched with 30 mL of water. The liquid was then separated and the organic phase was washed with 50 mL of 5%citric acid aqueous solution twice, and dried over sodium sulfate. After being filtered, the organic phase was concentrated and purified by column chromatography to give 5.17 g of a pale yellow oil, M1, with yield of 94%. (Reference: Org Lett. 2012 Jun 15; 14 (12) : 2940-3. )
2) Synthesis of M2
100 mL of dry DMF was added into 5 g (18.2 mmol) of M1, then 3A molecular sieve and sodium formate (3.7 g, 54 mmol) were added, with nitrogen replacement for three times. After 2.3 g (54 mmol) of lithium chloride added into the reaction, the reaction was put into ice bath, and acetic anhydride (3.7 g, 36 mmol) and diisopropylamine (3.6 g, 36 mmol) were added dropwise. The reaction was warmed up to room temperature, and palladium acetate (0.4 g, 1.8 mmol) was added. After continuous stirring for 24 h, the reaction was cooled to temperature below 5℃, and 50 mL of 2N HCI was added dropwise within 5 min, continuously stirred for 10 min. The solution was extracted with 50 mL of ethyl acetate for three times, and then washed with 50 mL of saturated sodium chloride solution twice. The product was dried with anhydrous magnesium sulfate, filtered, concentrated, and purified by column chromatography. 1.17 g of M2 was achieved, with yield of 47%. (Reference: Angew Chem Int Ed Engl. 2015 Jan 26; 54 (5) : 1527-31)
2. Synthesis of FD1
1 mL of concentrated ammonia and 3 g of anhydrous sodium sulfate were added into 5 mL of dichloromethane, stirred in ice bath for 30 min. This reaction gave the solution of ammonia in methylene chloride. 5 mL of dichloromethane and 1 g of thionyl chloride was added into 150 mg (0.42 mmol) of vidofludimus, reflux reaction for 4 h. The organic solvent was removed by concentration under reduced pressure. 2 mL of dichloromethane was added with stirring in ice bath, then 2.5 mL of the solution of ammonia in methylene chloride was added into the reaction dropwise. After that, the reaction was warmed up to room temperature, stirred continuously for 5 h. Then, 10 mL of dichloromethane and 5 mL of water were added. After stirring for 5 min, the liquid was separated. The organic phase was washed with 5 mL of water twice, dried with anhydrous sodium sulfate, concentrated and purified by column chromatography. 108 mg of FD1 was achieved, with yield of 73%.
3. Synthesis of FD2
40%methylamine aqueous solution and 3 g of anhydrous sodium sulfate were added into 5 mL of dichloromethane, stirred in ice bath for 30 min. This reaction gave the solution of methylamine in methylene chloride. 5 mL of dichloromethane and 1 g of thionyl chloride were added into 150 mg (0.42 mmol) of vidofludimus, reflux reaction for 4 h. The organic solvent was removed by concentration under reduced pressure. 4 mL of dichloromethane was added with stirring in ice bath, then 1 mL of the solution of methylamine in methylene chloride was added into the reaction dropwise. After that, the reaction was warmed up to room temperature, stirred continuously for 5 h. Then, 5 mL of dichloromethane and 5 mL of water were added. After stirring for 5 min, the liquid was separated. The organic phase was washed with 5 mL of water for three times, dried with anhydrous sodium sulfate, concentrated and purified by column chromatography. 121 mg of FD2 was achieved, with yield of 78%.
4. Synthesis of FD3
5 mL of ethanol was added into 380 mg of thionyl chloride, which gave the solution of thionyl chloride in ethanol.
5 mL of ethanol was added into 150 mg (0.42 mmol) of vidofludimus, and then 1 mL of the solution of thionyl chloride in ethanol was added into the reaction. After warming up for reflux reaction for 3 h, the solvent was removed under reduced pressure. 5 mL of ethanol was added and the thionyl chloride was removed by concentration under reduced pressure twice. Then 10 mL of dichloromethane and 5 mL of water were added. After stirring for 10 min, the liquid was separated. The organic phase was washed with 5 mL of water for three times, dried with anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography. 128 mg of FD3 was achieved, with yield of 79.5%.
5. Synthesis of FD5
5 mL of anhydrous methanol was added into 380 mg of thionyl chloride, which gave the solution of dichlorosulfoxide in methanol. 5 mL of ethanol was added into 150 mg (0.42 mmol) of vidofludimus, and then 1 mL of the solution of dichlorosulfoxide in methanol was added into the reaction. After warming up for reflux reaction for 3 h, the solvent was removed under reduced pressure. 5 mL of ethanol was added and the thionyl chloride was removed by concentration under reduced pressure twice. Then 10 mL of dichloromethane and 5 mL of water were added. After stirring for 10 min, the liquid was separated. The organic phase was washed with 5 mL of water for three times, dried with anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography. 134 mg of FD5 was achieved, with yield of 86.5%.
6. Synthesis of FD6
1) Synthesis of M5
Toluene (9 mL) , ethanol (6 mL) and water (3 mL) were added into the mixture of M3 (0.95 g, 5 mmol) , 3-Methoxyboronic acid (0.83 g, 5 mmol) and potassium carbonate (1.73 g, 12.5 mmol) , stirred with nitrogen replacement for three times. Additional replacement with nitrogen was performed for three times after 0.3 g of tetraphenylphenylphosphine palladium was added. Then the reaction was warmed up for reflux reaction overnight. The product was filtered and concentrated, then 20 mL of dichloromethane and 10 mL of water were added and stirred for 10 min. The liquid was separated and washed with 10 mL of water twice, dried with anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography. With 0.73 g of M5 achieved.
2) Synthesis of FD6
5 mL of DCM was added into 138 mg (1.0 mmol) of M2 and stirred. Then M5 (231 mg, 1.0 mmol) was added into the reaction, and stirred for 24 h. After that, 5 mL of water was added and stirred for 5 min, the liquid was separated and dried with anhydrous sodium sulfate, concentrated and purified by column chromatography. 210 mg of FD6 was achieved, with yield of 57%.
7. Synthesis of FD9
1) Synthesis of M6
Toluene (9 mL) , ethanol (6 mL) and water (3 mL) were added into the mixture of M3 (0.95 g, 5 mmol) , 3-Methylboronic acid (0.68 g, 5 mmol) and potassium carbonate (1.73 g, 12.5 mmol) , stirred with nitrogen replacement for three times. Additional replacement with nitrogen was performed for three times after 0.3 g of tetraphenylphenylphosphine palladium was added. Then the reaction was warmed up for reflux reaction overnight. The product was filtered and concentrated, then 20 mL of dichloromethane and 10 mL of water were added and stirred for 10 min. The liquid was separated and washed with 10 mL of water twice, dried with anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography. 0.73 g of M6 was achieved.
2) Synthesis of FD9
5 mL of DCM was added into 138 mg (1.0 mmol) of M2 and stirred. Then M5 (231 mg, 1.0 mmol) was added into the reaction, and stirred for 24 h. After that, 5 mL of water was added and stirred for 5 min, the liquid was separated and dried with anhydrous sodium sulfate, concentrated and purified by column chromatography. 210 mg of FD9 was achieved, with yield of 57%
8. Synthesis of FD10
1) Synthesis of M7
Toluene (9 mL) , ethanol (6 mL) and water (3 mL) were added into the mixture of M3 (0.95 g, 5 mmol) , 3-Methylboronic acid (0.75 g, 5 mmol) and potassium carbonate (1.73 g, 12.5 mmol) , stirred with nitrogen replacement for three times. Additional replacement with nitrogen was performed for three times after 0.3 g of tetraphenylphenylphosphine palladium was added. Then the reaction was warmed up for reflux reaction overnight. The product was filtered and concentrated, then 20 mL of dichloromethane and 10 mL of water were added and stirred for 10 min. The liquid was separated and washed with 10 mL of water twice, dried with anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography. 0.73 g of M7 was achieved.
2) Synthesis of FD10
5 mL of DCM was added into 138 mg (1.0 mmol) of M2 and stirred. Then M7 (211 mg, 1.0 mmol) was added into the reaction, and stirred for 24 h. After that, 5 mL of water was added and stirred for 5 min, the liquid was separated and dried with anhydrous sodium sulfate, concentrated and purified by column chromatography. 208 mg of FD9 was achieved, with yield of 56%
9. Synthesis of FD11
1) Synthesis of M8
Toluene (9 mL) , ethanol (6 mL) and water (3 mL) were added into the mixture of M3 (0.95 g, 5 mmol) , 3-Methylboronic acid (0.82 g, 5 mmol) and potassium carbonate (1.73 g, 12.5 mmol) , stirred with nitrogen replacement for three times. Additional replacement with nitrogen was performed for three times after 0.3 g of tetraphenylphenylphosphine palladium was added. Then the reaction was warmed up for reflux reaction overnight. The product was filtered and concentrated, then 20 mL of dichloromethane and 10 mL of water were added and stirred for 10 min. The liquid was separated and washed with 10 mL of water twice, dried with anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography. 0.77 g of M8 was achieved.
2) Synthesis of FD11
5 mL of DCM was added into 138 mg (1.0 mmol) of M2 and stirred. Then M8 (241 mg, 1.0 mmol) was added into the reaction, and stirred for 24 h. After that, 5 mL of water was added and stirred for 5 min, the liquid was separated and dried with anhydrous sodium sulfate, concentrated and purified by column chromatography. 230 mg of FD11 was achieved, with yield of 67%.
10. Synthesis of FD12
1) Synthesis of M10
Toluene (9 mL) , ethanol (6 mL) and water (3 mL) were added into the mixture of M0 (0.95 g, 5 mmol) , (3-methoxyphenyl) boronic acid (0.76 g, 5 mmol) and potassium carbonate (1.73 g, 12.5 mmol) , stirred with nitrogen replacement for three times. Additional replacement with nitrogen was performed for three times after 0.3 g of tetraphenylphenylphosphine palladium was added. Then the reaction was warmed up for reflux reaction overnight. The product was filtered and concentrated, then 20 mL of dichloromethane and 10 mL of water were added and stirred for 10 min. The liquid was separated and washed with 10 mL of water twice, dried with anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography. 0.713 g of M10 was achieved.
2) Synthesis of FD12
5 mL of DCM was added into 138 mg of M2 and stirred. Then M10 (221 mg, 1.0 mmol) was added into the reaction, and stirred for 24 h. After that, 5 mL of water was added and stirred for 5 min, the liquid was separated and dried with anhydrous sodium sulfate, concentrated and purified by column chromatography. 205 mg of FD12 was achieved, with yield of 58%.
11. Synthesis of FD13
1) Synthesis of M6
Toluene (9 mL) , ethanol (6 mL) and water (3 mL) were added into the mixture of M11 (1.02 g, 5 mmol) 4-bromo-2-chloroaniline, (3-methoxyphenyl) boronic acid (0.76 g, 5 mmol) and potassium carbonate (1.73 g, 12.5 mmol) , stirred with nitrogen replacement for three times. Additional replacement with nitrogen was performed for three times after 0.3 g of tetraphenylphenylphosphine palladium was added. Then the reaction was warmed up for reflux reaction overnight. The product was filtered and concentrated, then 20 mL of dichloromethane and 10 mL of water were added and stirred for 10 min. The liquid was separated and washed with 10 mL of water twice, dried with anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography. 0.83 g of M12 was achieved, with yield of 63%.
2) Synthesis of FD13
5 mL of DCM was added into 138 mg (1.0 mmol) of M2 and stirred. Then M12 (231 mg, 1.0 mmol) was added into the reaction, and stirred for 24 h. After that, 5 mL of water was added and stirred for 5 min, the liquid was separated and dried with anhydrous sodium sulfate, concentrated and purified by column chromatography. 230 mg of FD13 was achieved, with yield of 67%.
12. Synthesis of FD20
1) Synthesis of M13
Toluene (9 mL) , ethanol (6 mL) and water (3 mL) were added into the mixture of M0 (0.95 g, 5 mmol) 4-bromo-2-chloroaniline, (3-ethylphenyl) boronic acid (0.75 g, 5 mmol) and potassium carbonate (1.73 g, 12.5 mmol) , stirred with nitrogen replacement for three times. Additional replacement with nitrogen was performed for three times after 0.3 g of tetraphenylphenylphosphine palladium was added. Then the reaction was warmed up for reflux reaction overnight. The product was filtered and concentrated, then 20 mL of dichloromethane and 10 mL of water were added and stirred for 10 min. The liquid was separated and washed with 10 mL of water twice, dried with anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography. 0.67 g of M13 was achieved, with yield of 64%.
2) Synthesis of FD20
5 mL of DCM was added into 138 mg (1.0 mmol) of M2 and stirred. Then M13 (211 mg, 1.0 mmol) was added into the reaction, and stirred for 24 h. After that, 5 mL of water was added and stirred for 5 min, the liquid was separated and dried with anhydrous sodium sulfate, concentrated and purified by column chromatography. 244 mg of FD20 was achieved, with yield of 70%.
13. Synthesis of FD29
1) Synthesis of M14
Toluene (9 mL) , ethanol (6 mL) and water (3 mL) were added into the mixture of M0 (0.95 g, 5 mmol) 4-bromo-2-chloroaniline, m-tolylboronic acid (0.68 g, 5 mmol) and potassium carbonate (1.73 g, 12.5 mmol) , stirred with nitrogen replacement for three times. Additional replacement with nitrogen was performed for three times after 0.3 g of tetraphenylphenylphosphine palladium was added. Then the reaction was warmed up for reflux reaction overnight. The product was filtered and concentrated, then 20 mL of dichloromethane and 10 mL of water were added and stirred for 10 min. The liquid was separated and washed with 10 mL of water twice, dried with anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography. 0.72 g of M14 was achieved, with yield of 72%.
2) Synthesis of FD29
5 mL of DCM was added into 138 mg (1.0 mmol) of M2 and stirred. Then M14 (197 mg, 1.0 mmol) was added into the reaction, and stirred for 24 h. After that, 5 mL of water was added and stirred for 5 min, the liquid was separated and dried with anhydrous sodium sulfate, concentrated and purified by column chromatography. 227 mg of FD13 was achieved, with yield of 68%
14. Synthesis of FD31
1) Synthesis of M15
Toluene (9 mL) , ethanol (6 mL) and water (3 mL) were added into the mixture of M0 (0.95 g, 5 mmol) 4-bromo-2-chloroaniline, (3-isopropylphenyl) boronic acid (0.82 g, 5 mmol) and potassium carbonate (1.73 g, 12.5 mmol) , stirred with nitrogen replacement for three times. Additional replacement with nitrogen was performed for three times after 0.3 g of tetraphenylphenylphosphine palladium was added. Then the reaction was warmed up for reflux reaction overnight. The product was filtered and concentrated, then 20 mL of dichloromethane and 10 mL of water were added and stirred for 10 min. The liquid was separated and washed with 10 mL of water twice, dried with anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography. 0.83 g of M15 was achieved, with yield of 73%.
2) Synthesis of FD31
5 mL of DCM was added into 138 mg (1.0 mmol) of M2 and stirred. Then M15 (225 mg, 1.0 mmol) was added into the reaction, and stirred for 24 h. After that, 5 mL of water was added and stirred for 5 min, the liquid was separated and dried with anhydrous sodium sulfate, concentrated and purified by column chromatography. 254 mg of FD31 was achieved, with yield of 69%
Table 2. Chemical No., names, structures and
1H-NMR data for compounds disclosed herein.
Example 3. Therapeutic effects of compounds on liver injury.
Methods: Acetaminophen (APAP) -induced liver injury in mouse is a commonly used model to study drugs in protecting liver. Overdose of APAP causes liver injury by inducing the production of reactive oxygen species and reactive nitrogen species, and excessive consumption of reductive substances such as antioxidant glutathione (GSH) , leading to the reduction of GSH in vivo, and the following upregulation of the activities of the aspartate aminotransferase (AST) the alanine aminotransferase (ALT) , the alkaline phosphatase (ALP) and the lactate dehydrogenase (LDH) , which will result in liver inflammation and necrosis. In this example, the APAP-induced liver injury was used to detect the protective and repairing functions of our compounds in liver injury.
17-week-old male C57BL/6J mice were maintained under environmentally controlled conditions with free access to standard chow diet and water. Animal experiments were conducted in the barrier facility of the Laboratory Animal Center, Xiamen University, approved by the Institutional Animal Use and Care Committee of Xiamen University, China.
We selected vidofludimus, vidofludimus sodium salt and vidofludimus calcium salt to test the hepatoprotective effects of our compounds. Compounds were solved with DMSO and then prepared to work concentration with 40%HBC (2-hydroxypropyl-β-cyclodextrin) in which the final work concentrations of compounds are 10 mg/kg body weight in 200 μl injection volume and the concentration of DMSO is 10%. Compounds were intraperitoneal (i.p. ) injected once daily for five days. Six hours after the fifth injection, 500 mg/kg body weight of APAP solved in PBS was i.p. injected to the mice. 24 hours later, mice were sacrificed. Part of each liver was fixed in 4%paraformaldehyde, and the liver histology characterization was analyzed by haematoxylin and eosin (H&E) staining with paraffin-embedded sections by standard procedures. Other liver tissues were collected for detecting the reduced GSH levels using Reduced Glutathione Kit (Nanjing Jiancheng Bioengineering Institute, China) , and the mRNA expression of genes involved in liver repairing, such as GCLM and UGT1a1, by RT-PCR. GCLM is the gene encoding the modifier subunit of the glutamate cysteine ligase GCLM, which is the rate-limiting enzyme in GSH biosynthesis. UGT1a1 is a uridine diphosphate glucuronosyltransferase (UDP-glucuronosyltransferase, UDPGT) , an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. Mutations in this gene cause serious problems for bilirubin metabolism. The serums were collected to measure enzymes activities including AST, ALT, ALP and LDH using kits from Nanjing Jiancheng Bioengineering Institute, China.
For Real-time quantitative PCR (RT-qPCR) , Total RNA was isolated using Tissue RNA kit (Omega Bio-Tek, GA) . The first strand cDNA was obtained by TAKARA reverse transcription kit. RT-qPCR was performed on a CFX96
TM Real-Time PCR Detection System (Bio-Rad) using SYBR Premix Ex TaqTM (TAKARA) . Relative mRNA expression levels were normalized to GAPDH levels.
Results: As shown in Figure 2, the pathological sections in control group displayed obvious cell infiltration, vacuolization and necrosis in hepatic lobule. There were a large number of inflammatory cell infiltration, cell turbidity, dissolved karyopycnosis or broken in lobules and portal area. And liver cell cords were also blurred. Compared to the severe liver injury in the control group, pre-treated with vidofludimus, vidofludimus sodium salt and vidofludimus calcium salt obviously protected liver from injury. After the treatment with the compounds, the activities of serum AST, ALT, ALP and LDH were dramatically lower (Table 3) , the reduced GSH levels in liver tissues were increased (Table 3) , and the expression levels of GCLM and UGT1A1 were significantly upregulated than those in the vehicle control group (Table 3) . These results indicated the protective and repairing functions of the compounds in the pre-treatment of APAP-induced liver injury, demonstrating that vidofludimus and its pharmaceutically acceptable salts have therapeutic effects on liver injury.
Soluble oligomeric amyloid beta (Aβ) species are now considered to be of major pathological importance in Alzheimer's disease (AD) . Aβ-induced oxidative stress can be due to either an increase in ROS or a decrease in endogenous antioxidants like GSH and the activities of antioxidant enzymes. Up-regulation of reduced GSH may be protective against the oxidative and neurotoxic effects of oligomeric Aβ. Thus, our results showed that vidofludimus treatment efficaciously increased the level of GSH by upregulating the expression of GCLM, indicating the potential therapeutic roles of our compounds in treating AD.
Table 3. The effects of vidofludimus and its salt forms on the biomarkers for liver health.
a, p<0.05 (Student’s t-test) , n=2 per group. NA, not available.
Example 4. Effects of compounds on metaboli diseases mouse model.
Methods: In this example, we used ob/ob mouse (B6/JNju-Lep
em1Cd25/Nju) as an obese mouse model, and db/db mouse (BKS. Cg-Dock7m +/+ Leprdb/JNju) as an animal model of type II diabetes. These model mice were used to detect the functions of our compounds on metabolic diseases.
We first selected vidofludimus, its sodium salt and calcium salt to test their metabolic regulatory functions using ob/ob and db/db mice. 10-11 week-old male mice were maintained under environmentally controlled conditions with free access to water. Animal experiments were conducted in the barrier facility of the Laboratory Animal Center, Xiamen University, approved by the Institutional Animal Use and Care Committee of Xiamen University, China. In the example, mice were fed with high-fat diet (HFD, Research Diets, D12492) and treated with either vehicle (40%HBC) or compounds (10 mg/kg body weight) dissolved in vehicle by intra-peritoneally (i.p. ) injection once a day for 10 days. After the last compound-treatment, mice were fasted for 6 hours with free access to water, and then sacrificed. Part of each liver was fixed in 4%paraformaldehyde for haematoxylin and eosin (H&E) staining; part of each liver was frozen for oil red O staining, and other liver tissues were stored in liquid nitrogen for triglyceride and cholesterol measurement using Triglyceride Assay Kit and Cholesterol Assay Kit (Applygen, Beijing, China; Nanjing Jiancheng Bioengineering Institute, China) . Liver histology characterization was analyzed through H&E staining with paraffin-embedded sections by standard procedures. For oil red O staining, fresh liver tissues were embedded in optimum cutting temperature compound (OCT) and cryosectioned. The sections were fixed in 4%paraformaldehyde in PBS, and were stained with 0.3%oil red O according to standard procedures. The serums were collected to measure serum glucose, cholesterol and triglyceride levels using glucose oxidase method (Applygen, Beijing, China) , Cholesterol Assay Kit and Triglyceride Assay Kit (Nanjing Jiancheng Bioengineering Institute, China) , respectively. The serum levels of uric acid (UA) and ALP were measured with kits from Nanjing Jiancheng Bioengineering Institute; the mouse high sensitivity c-reactive protein, hs-crp ELISA KIT (BioLab, Beijing, China) was used to measure the serum CRP level, and the Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem., USA) was used to measure the serum insulin level.
We then selected synthetic compounds to test their regulatory functions on metabolism using ob/ob mouse model. 10-11 week-old male mice were treated with compounds (10 mg/kg body weight) for 14 d as mentioned above in this example. Serum metabolic parameters were measured. Liver and intestine tissues were stored in liquid nitrogen for gene expression analysis by RT-qPCR.
All data are expressed as means ± s.e.m. Statistical significance was analyzed using Student’s t-test. P values less than 0.05 were considered significant.
Results: After compound treatment for 10 days, the liver from mice treated with compounds displayed obvious difference in pathology. As shown in Table 4 and Table 5, the liver/body weight ratios were significantly decreased in compounds treated ob/ob and db/db mice. Importantly, the hepatic triglyceride and cholesterol levels were all significantly decreased in compounds treated mice. Moreover, as shown in Figure 3A and Figure 4A, the histological examination of liver sections obtained from vehicle treated mice showed the extensive existence of vesicular hepatocyte vacuolation, while compounds treatment efficaciously reversed the liver from hepatic steatosis in db/db mice with disappeared hepatic lipid accumulation and showed tight compact structure of the liver cells. The images of liver sections from oil red O staining further confirmed the therapeutic effects of compounds on hepatic lipid accumulation. As shown in Figure 3B and Figure 4B, liver sections from vehicle treated mice showed abundant lipid accumulation, especially containing many large lipid droplets, while liver sections from mice treated with compounds dramatically reduced the lipid accumulation. Patients suffering from non-alcoholic fatty liver disease (NAFLD) display a variety of hepatic dysfunctions, ranging from abnormal triglyceride accumulation in hepatocytes (steatosis) to steatohepatitis (non-alcoholic steatohepatitis, NASH) with fibrosis. Our results demonstrate that our compounds are efficacious drug candidates for treating fatty liver diseases, such as NAFLD and NASH. These data also indicate the therapeutic effects of our compounds on obesity.
Table 4. The effects of vidofludimus and its salt forms on the metabolic parameters of HFD-fed ob/ob mice.
a, p<0.05; b, p<0.01 (Student’s t-test) , n=3-4 per group
Table 5. The effects of vidofludimus and its salt forms on the metabolic parameters of HFD-fed db/db mice.
a, p<0.05; b, p<0.01; c, p<0.001 (Student’s t-test) , n=3-4 per group
Table 6. The treatment of compounds down-regulated the serum metabolic parameters in HFD-fed ob/ob mice.
a, p<0.05; b, p<0.01; c, p<0.001 (Student’s t-test) , n=1-3 per group.
Table 7. The compounds regulated mRNA levels of genes related to metabolism in liver of HFD-fed ob/ob mice.
a, p<0.05; b, p<0.01 (Student’s t-test) , n=2-3 per group
The serum cholesterol levels were significantly lowered in compounds treated ob/ob and db/db mice (Table 4, Table 5 &Table 6, indicating the therapeutic effects of the compounds on hypercholesterolemia. The serum triglyceride levels were significantly lowered in compounds treated ob/ob mice (Table 4 and Table 6) , indicating the therapeutic effects of the compounds on hypertriglyceridemia. The serum glucose levels were significantly lowered in compounds treated mice (Table 5 and Table 6) , indicating the therapeutic effects of our compounds on hyperglycemia and diabetes.
High levels of blood triglycerides and glucose are the alert indicators of cardiovascular disease. These indicators reflect the high risk for development of cardiovascular disease. In this example, the compounds treatment significantly decreased the blood levels of glucose and triglyceride, indicating their therapeutic effects on cardiovascular diseases.
Studies demonstrated that high total cholesterol level is positively correlated with the degree of carotid atherosclerotic plaque lesions. In this example, compounds treatment efficaciously decreased the serum cholesterol levels, indicating their therapeutic effects on atherosclerosis.
PPARα controls lipid flux in the liver by modulating FA transport and β-oxidation, and improves plasma lipid profiles by decreasing triglyceride (TG) levels and increasing high-density lipoprotein cholesterol levels. In addition, PPARα activation inhibits inflammatory genes induced by NF-κB, and decreases the expression of acute-phase response genes. Accordingly, PPARα deficiency increases susceptibility to NAFLD, NASH, hepatic inflammation and acute phase responses (see e.g., Ip E., et al., (2003) Hepatology; 38: 123–132) . It has been reported that expression of PPARα in human liver is reduced in patients with non-alcoholic steatohepatitis or infected with the hepatitis C virus. PPARαeffectively induces the expression of numerous genes involved in lipid metabolic pathways, including fatty acid elongation and desaturation, synthesis and breakdown of triglycerides and lipid droplets, gluconeogenesis, bile acid metabolism (see e.g., Kersten S. and Stienstra R., (2017) Biochimie. 136: 75-84) . SREBP-1c is responsible for regulating the genes required for de novo lipogenesis. G6PC is a key enzyme in glucose homeostasis. As shown in Table 7, our compounds increased the expression of PPARα and decreased the expression of SREBP1c and G6PC in liver.
Table 8. The treatment of compounds regulated mRNA levels of collagens in liver.
Compound | α1 (I) collagen | α2 (I) collagen | Compound | α1 (I) collagen | α2 (I) collagen |
Vehicle | 1.00±0.18 | 1.00±0.14 | FD11 | 0.52±0.17 a | 0.73±0.19 |
FD2 | 0.53±0.14 a | 0.52±0.16 a | FD12 | 0.35±0.14 a | 0.37±0.16 a |
FD3 | 0.37±0.17 a | 0.45±0.17 a | FD13 | 0.36±0.17 a | 0.48±0.14 a |
a, p<0.05 (Student’s t-test) , n=2-3 per group
NAFLD with excessive fat accumulation in liver will affect the blood and oxygen supplies to liver and the metabolism of liver organ, resulting in amounts of cell swelling, inflammatory infiltration and necrosis in liver. Once fibrosis and false lobules appear, cirrhosis will happen and the risk of liver cancer will be greatly increased. The levels of various collagen contents are higher in patients with liver cirrhosis. As shown in Table 8, the compounds decreased the mRNA levels of α1 (I) collagen and α2 (I) collagen, suggesting their effects in preventing NAFLD and cirrhosis.
Table 9. The treatment of compounds regulated FXR target genes and inflammatory genes.
a, p<0.05 (Student’s t-test) , n=2-3 per group
FGF15 plays an important role in feedback inhibition of hepatic bile acid synthesis. FXR directly binds to the response element of the promoter of FGF15 and regulates its expression. As shown in Table 9, the synthetic compounds increased the mRNA levels of FGF15, and efficaciously lowered the mRNA levels of inflammatory genes in both liver and intestine tissues, indicating their therapeutic effects on hepatitis and enteritis.
Table 10. The treatment of compounds decreased the levels of UA and CRP.
Compound | UA (μM) | CRP (μg/mL) | Compound | UA (μM) | CRP (μg/mL) |
Vehicle | 76.1±3.1 | 0.148±0.006 | FD5 | 50±9.2 | 0.089±0.024 a |
FD2 | 63.0±3.1 a | 0.080±0.005 c | FD12 | 47.8±12.3 | 0.074±0.016 b |
FD3 | 39.1 | 0.082 | FD13 | 50±3.1 a | 0.080±0.016 b |
a, p<0.05; b, p<0.01; c, p<0.001 (Student’s t-test) , n=1-3 per group
High blood concentrations of uric acid can lead to gout and are associated with other medical conditions including diabetes and the formation of ammonium acid urate kidney stones. C-reactive protein (CRP) is synthesized by the liver in response to factors released by macrophages and fat cells (adipocytes) (see e.g. Lau DC et al., (2005) Am J Physiol Heart Circ Physiol. 288: H2031–41. ) . Elevated levels of CRP are commonly found in gouty arthritis. As shown in Table 4 &10, our compounds decreased the serum level of UA and CRP, indicating the potential therapeutic effects of these compounds in treating gout and gouty arthritis.
Table 11. The treatment of compounds decreased serum ALP level in HFD-fed ob/ob mice. (n=2-3 per group)
Compound | ALP (U/L) | Compound | ALP (U/L) |
Vehicle | 38.5±6.8 | FD9 | 28.8±4.9 |
FD1 | 30.1±0.1 | FD10 | 30.3±2.9 |
FD2 | 31.3±1.4 | FD11 | 27.7±6.5 |
Except in liver disease or hepatitis, elevated ALP is also commonly found in diseases and conditions including biliary obstruction, bone conditions, osteoblastic bone tumors, osteomalacia, osteoporosis, etc. As shown in Table 11, there is a trend for some of the synthetic compounds to decrease the serum levels of ALP. These data suggested that our compounds might be curative in treating bone conditions including osteoporosis.
Table 12. The treatment of compounds decreased serum BUN levels in HFD-fed ob/ob mice. (n=2-3 per group)
Compound | BUN (mM) | Compound | BUN (mM) |
Vehicle | 5.94±0.55 | FD5 | 4.60±1.04 |
FD1 | 4.77±0.03 | FD10 | 5.45±0.44 |
FD3 | 4.89±0.27 | FD12 | 4.73±0.33 |
The blood urea nitrogen (BUN) concentration will increase rapidly when the filtration ratio in glomerular decrease lower than 50%. Various renal parenchymal diseases, including glomerulonephritis, interstitial nephritis, acute and chronic renal failure, renal lesions and renal destructive lesions, can increase the BUN levels. Therefore, BUN is a main indicator for kidney function, as well as the uremia. The BUN levels were measured with the Urea Assay kit (Nanjing Jiancheng Bioengineering Institute, China) in this example, and the results showed that the compounds decreased the BUN levels in HFD-fed ob/ob mice (Table 4, 5 &12) , suggesting the therapeutic effects of our compounds on various kidney diseases including glomerulonephritis, interstitial nephritis, acute and chronic renal failure, renal lesions, renal destructive lesions and uremia that have increased BUN.
Example 5. Effects of compounds on ob/ob mice administrated by oral gavage.
Methods: Compounds were prepared to work concentration with 0.5% (w/v) carboxymethycellulose (CMC-Na) in PBS. 7-8 week-old male ob/ob mice were treated with vidofludimus (5 mg/kg body weight) , other compounds (20 mg/kg body weight) , or 0.5%CMC-Na as vehicle controls by daily oral gavage for 4 weeks. Liver tissues and serum samples were collected for metabolic parameters measurement as mentioned in example 4. The serum level of free fatty acids (FFA) was measured with kits from Nanjing Jiancheng Bioengineering Institute.
Results: As shown in Table 13, compounds treatment by orally gavage decreased the activities of AST and ALT, indicating the safety of these compounds to liver functions, and also their hepatoprotective functions.
Table 13. The effects of compounds on the serum AST and ALT.
Compound | AST (U/L) | ALT (U/L) | Compound | AST (U/L) | ALT (U/L) |
Vehicle | 73.15±10.13 | 89.35±2.56 | FD13 | 61.67±5.11 | 73.82±9.17 a |
FD6 | 42.54 | 52.66 | FD20 | 54.69 | 72.25 |
FD9 | 47.60±8.12 | 64.82±8.59 a | FD29 | 39.16±5.73 a | 47.60±6.21 b |
FD10 | 36.80±4.30 a | 46.59±0.95 c | FD31 | 55.03±11.94 | 65.49±7.64 a |
FD11 | 57.39 | 74.27 | vidofludimus | 50.98±20.53 | 69.88±28.17 |
FD12 | 53.00±0.48 | 67.18±7.16 a |
a, p<0.05; b, p<0.01; c, p<0.001 (Student’s t-test) . n=1-3 per group.
The levels of the serum FFA (Table 14) , triglycerides (Table 15) , UA (Table 16) and the hepatic level of total cholesterol (Table 17) of mice were reduced in the compounds treated mice, and the mRNA expression levels of inflammatory factors (Table 18) in liver tissues were down-regulated in the compounds treated mice. As discussed in example 4, these data suggest that our compounds are potential drug candidates for treating diseases such as fatty liver diseases, hypertriglyceridemia, hepatitis, gout and gouty arthritis. This example also indicates that orally administrated with our compounds are also efficacious in treating metabolic diseases.
Table 14. The effects of compounds on the serum level of FFA.
Compound | FFA (mM) | Compound | FFA (mM) |
Vehicle | 1.94±0.06 | FD12 | 1.72±0.08 a |
FD4 | 1.22 | FD13 | 1.63±0.06 b |
FD6 | 1.17 | FD20 | 1.35±0.26 a |
FD9 | 1.74±0.06 a | FD29 | 0.83 |
FD10 | 1.39±0.39 | FD31 | 1.25±0.39 a |
FD11 | 1.57±0.61 | vidofludimus | 1.32±0.06 b |
a, p<0.05; b, p<0.01 (Student’s t-test) . n=1-3 per group.
Table 15. The effects of compounds on the serum level of triglycerides. (n=2-3 per group)
Table 16. The effects of compounds on the serum level of UA. (n=2-3 per group)
Compound | UA (mM) | Compound | UA (mM) |
Vehicle | 220.88±25.98 | FD29 | 175.76±38.01 |
FD20 | 123.23±25.71 | FD31 | 135.35±82.85 |
Table 17. The effects of compounds on the level of hepatic cholesterol.
Compound | Total Cholesterol (mg/g) | Compound | Total Cholesterol (mg/g) |
Vehicle | 4.18±1.11 | FD13 | 1.71±0.26 a |
FD6 | 2.89 | FD20 | 2.63±0.19 |
FD9 | 2.26±0.05 | FD29 | 3.19±1.41 |
FD10 | 2.53±0.38 | FD31 | 1.58±0.07 a |
FD12 | 1.92±0.64 | vidofludimus | 2.35±0.26 |
a, p<0.05 (Student’s t-test) . n=1-3 per group.
Table 18. The effects of compounds on the mRNA levels of inflammatory factors in liver tissues.
Compound | α-SMA | IL-1β | Compound | α-SMA | IL-1β |
Vehicle | 1.06±0.21 | 1.00±0.25 | FD12 | 0.35±0.16 a | 0.48±0.27 |
FD4 | 0.37 | 0.77 | FD13 | 0.38±0.21 a | 0.57±0.23 |
FD6 | 0.42 | 0.49 | FD20 | 0.60±0.25 | 0.46±0.19 a |
FD9 | 0.54±0.34 | 0.38±0.19 a | FD29 | 0.32±0.19 a | 0.55±0.23 a |
FD10 | 0.27 | 0.46±0.21 | FD31 | 0.34±0.19 a | 0.66±0.17 |
FD11 | 0.42±0.18 a | 0.38±0.16 a | Vidofludimus | 0.32±0.22 a | 0.53±0.24 |
a, p<0.05 (Student’s t-test) . n=1-3 per group.
Example 6. Therapeutic effects on DSS-induced enteritis.
Methods: Dextran sodium sulfate (DSS) challenge in mice causes intestinal inflammation and injury that resembles human colitis (see e.g. Wirtz et al., (2007) Nature protocols 2, 541-546) . In this example, mouse model with DSS-induced intestinal inflammation was used to test the therapeutic effects of our compounds in treating enteritis.
Compounds were prepared to work concentration with 0.5% (w/v) carboxymethycellulose (CMC-Na) in PBS. 8-9 week-old male wild-type mice were treated with compounds (20 mg/kg body weight) or 0.5%CMC-Na as vehicle controls by daily oral gavage for 13 days. Mice received 2.5% (w/v) DSS in drinking water on days 4-13. Ilea were collected for measurement of the inflammatory genes expression, and colons were fixed in 10%formalin and embedded in paraffin for H&E staining.
Results: As shown in Figure 5, DSS challenge to mice resulted in goblet cell loss, colonic epithelial damage and ulceration. Compared with the vehicle control, compounds treatment obviously improved the colonic epithelial damage and ulceration, with much less goblet cell loss, which is consistent with the larger ratio of final/initial body weight of mice with compounds treatment (Table 19) .
Inflammatory cytokines are produced during inflammation, and thus are markers of the inflammatory reaction. In this example, we detected the levels of various inflammatory cytokines including COX2, IL-1β, IL-17 and MIP-1α in ilea from the treated mice. As shown in Table 20, compounds treatment decreased the inflammatory cytokines levels in DSS-induced colitis models, demonstrating the therapeutic effects of compounds in treating enteritis.
Table 19. Compounds improved final/initial body weight ratio.
a, p<0.05; c, p<0.001 (Student’s t-test) , n=2-3 per group
Table 20. Compounds regulated mRNA expression of FXR target gene and inflammatory factors.
Compound | FGF15 | COX2 | MCP1 | IL-17 | IL-1β |
Vehicle | 1.66±0.31 | 17.62±2.52 | 10.10±1.60 | 20.39±4.19 | 5.16±0.55 |
FD1 | 2.41±0.40 | 13.65±1.58 | 4.97±1.05 a | 11.75±2.14 a | 3.08±0.79 a |
FD3 | 193.69±8.32 a | 9.14±1.85 a | 2.27±0.42 b | 9.80±1.04 a | 4.00±0.26 |
FD12 | 67.19±9.25 a | 3.25±0.76 c | 4.45±0.99 c | 2.20±1.04 c | 3.50±0.56 b |
FD13 | 19.83±3.78 a | 4.37±1.01 a | 1.48±0.39 b | 1.89±0.90 b | 1.31±0.16 b |
a, p<0.05; b, p<0.01; c, p<0.001 (Student’s t-test) , n=2-3 per group
Example 7. Therapeutic effects on arthritis.
Methods: As mentioned above in the BACKGROUND, TNFα secreted from the macrophages has becoming an indicator of activity in arthritis and a target for treating arthritis. In this example, 8-week-old male C57BL/6J mice were injected with sterile thioglycolic acid broth into the peritoneum. 3 days after injection, mice were sacrificed and injected with 10 mL of RPMI-1640 medium containing 5%FBS into the peritoneum to harvest peritoneal macrophages. Collected cells were centrifuged at 160×g for 5 min, and the cell pellet was washed with PBS and centrifuged again. The cell pellet was then suspended in RPMI-1640 medium supplemented with 100 U/mL of penicillin, 100 μg/mL of streptomycin and 10%FBS, and plated into 12-well plates. After incubation at 37 ℃ for 3 h, the cells were washed with PBS three times to remove unattached cells such as neutrophils, and then cultured in the same RPMI-1640 medium. 24 h after the cells were plated into the wells, 10 uM of compounds were added into the culture medium. Additional 2 h later, 0.5 ug/mL of LPS were added into the culture medium, and cells were harvested in 22 h. The media were collected and the secreted TNFα in the medium were detected using the Mouse TNFα ELISA kit (NeoBioscience) .
Results: As shown in Table 21, following the stimulation with LPS alone, peritoneal macrophages produced high level of TNFα. In combined with our compounds treatment, the production of TNFα were obviously suppressed, suggesting the roles of compounds in treating arthritis, such as RA, OA, JIA and so on.
Table 21. Compounds suppressed the production of TNFα in LPS-induced macrophages.
Claims (16)
- A method for treating an FXR-mediated process or disease in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound having the formula:or in a pharmaceutically acceptable carrier and/or diluent form thereof, wherein R1 is independently selected from hydrogen, hydroxy, methoxy, ethoxy, amino, methylamine, dimethylamine, trimethylamine, lower amines, or lower alkoxy group; R2 is independently selected from hydrogen, halogen, sulfur, or lower alkyl group; and R3 is methoxy, methyl, ethyl, propyl, 1-methylethyl, non-isomeric cyclopropyl, lower alkyl group or other hydrophobic groups.
- The compound according to claim 1, wherein R1 is hydroxyl; R2 is independently selected from halogen; and R3 is a methoxy group.
- A pharmaceutical composition comprising a pharmaceutical acceptable vehicle and at least one compound having the formula:or in a pharmaceutically acceptable carrier and/or diluent form thereof, wherein R1 is independently selected from amino, methylamine, dimethylamine, trimethylamine, or ethoxy group; R2 is independently selected from hydrogen, halogen, or lower alkyl group; and R3 is methoxyl, methyl, ethyl, propyl, 1-methylethyl, non-isomeric cyclopropyl, lower alkyl group or other hydrophobic groups.
- The compound according to claim 3, wherein R1 is independently selected from amino, methylamine, or ethoxy group; R2 is independently selected from halogen; and R3 is methoxyl, methyl, ethyl, or propyl.
- A pharmaceutical composition comprising a pharmaceutical acceptable vehicle and at least one compound having the formula:or in a pharmaceutically acceptable carrier and/or diluent form thereof, wherein R1 is independently selected from hydroxyl or methoxyl group; R2 is independently selected from hydrogen, halogen, or lower alkyl group; R3 is methyl, ethyl, propyl, 1-methylethyl, non-isomeric cyclopropyl, lower alkyl group or other hydrophobic groups.
- The compound according to claim 5, wherein R1 is hydroxyl; R2 is independently selected from halogen; and R3 is methyl, ethyl, or 1-methylethyl.
- A pharmaceutical composition comprising a pharmaceutical acceptable vehicle and at least one compound having the formula:or in a pharmaceutically acceptable carrier and/or diluent form thereof, wherein R1 is independently selected from hydrogen, hydroxy, methoxy, ethoxy, amino, methylamine, dimethylamine, trimethylamine, lower amines, or lower alkoxy group; R2 is independently selected from hydrogen, or lower alkyl group; and R3 is methoxyl, methyl, ethyl, propyl, 1-methylethyl, non-isomeric cyclopropyl, lower alkyl group or other hydrophobic groups.
- The compound according to claim 7, wherein R1 is hydroxyl, methoxyl, amino, or methylamine; R2 is a methyl group; and R3 is methoxyl, methyl, ethyl, or 1-methylethyl.
- The compound according to claim 3, 5 or 7 selected from the group consisting of the following:N- (3-fluoro-3'-methoxy- [1, 1'-biphenyl] -4-yl) cyclopent-1-ene-1, 2-dicarboxamideN 1- (3-fluoro-3'-methoxy- [1, 1'-biphenyl] -4-yl) -N 2-methylcyclopent-1-ene-1, 2-dicarboxamid eethyl2- ( (3-fluoro-3'-methoxy- [1, 1'-biphenyl] -4-yl) carbamoyl) cyclopent-1-ene-1-carboxylate methyl2- ( (3-fluoro-3'-methoxy- [1, 1'-biphenyl] -4-yl) carbamoyl) cyclopent-1-ene-1-carboxylate2- ( (3'-ethoxy-3-fluoro- [1, 1'-biphenyl] -4-yl) carbamoyl) cyclopent-1-ene-1-carboxylic acid2- ( (3-fluoro-3'-methyl- [1, 1'-biphenyl] -4-yl) carbamoyl) cyclopent-1-ene-1-carboxylic acid;2- ( (3'-ethyl-3-fluoro- [1, 1'-biphenyl] -4-yl) carbamoyl) cyclopent-1-ene-1-carboxylic acid;2- ( (3-fluoro-3'-isopropyl- [1, 1'-biphenyl] -4-yl) carbamoyl) cyclopent-1-ene-1-carboxylic acid;2- ( (3'-methoxy-3-methyl- [1, 1'-biphenyl] -4-yl) carbamoyl) cyclopent-1-ene-1-carboxylic acid;2- ( (3-chloro-3'-methoxy- [1, 1'-biphenyl] -4-yl) carbamoyl) cyclopent-1-ene-1-carboxylic acid;2- ( (3'-ethyl-3-methyl- [1, 1'-biphenyl] -4-yl) carbamoyl) cyclopent-1-ene-1-carboxylic acid;2- ( (3, 3'-dimethyl- [1, 1'-biphenyl] -4-yl) carbamoyl) cyclopent-1-ene-1-carboxylic acid;2- ( (3'-isopropyl-3-methyl- [1, 1'-biphenyl] -4-yl) carbamoyl) cyclopent-1-ene-1-carboxylic acid.
- A method for treating an FXR-mediated process or disease in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claims 2-9.
- The method of claim 1 or 10, wherein the FXR-mediated process or disease is selected from: cholestasis; colitis; Alzheimer's disease; a chronic liver disease selected from primary biliary cirrhosis, primary sclerosing cholangitis, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis; a gastrointestinal disease selected from inflammatory bowel disease, irritable bowel syndrome, bacterial over-growth, and malabsorption; a cardiovascular disease selected from atherosclerosis, arteriosclerosis, dyslipidemia, hypercholesterolemia, and hypertriglyceridemia; a metabolic disease selected from insulin resistance, hyperglycemia, Type I and Type II diabetes, and obesity; a disorder related to bone formation such as osteoporosis, bone hyperplasia and osteoarthritis; an autoimmune and inflammatory disease selected from rheumatoid arthritis, tendinitis or bursitis, fibromyalgia, muscular low back pain, chronic obstructive pulmonary disease (COPD) , psoriasis, pelvic inflammatory disease (PID) , asthma, pneumonia, polymyalgia rheumatica and gout; and a kidney disease selected from diabetic nephropathy, focal segmental glomerulosclerosis, chronic glomerulonephritis, interstitial nephritis, acute and chronic renal failure, renal lesions, renal destructive lesions and uremia.
- A method for liver protection or treatment of hepatic injury comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 1-9.
- A method for lowing alanine aminotransferase (ALT) , aspartate aminotransferase (AST) or alkaline phosphatase (ALP) comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 1-9.
- A method for lowing triglyceride comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 1-9.
- A method for treating nonalcoholic fatty liver disease, nonalcoholic steatohepatitis or atherosclerosis comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 1-9.
- A method for treating inflammatory bowel disease or rheumatoid arthritis comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 3-9.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710192430.1 | 2017-03-28 | ||
CN201710192430.1A CN108653260B (en) | 2017-03-28 | 2017-03-28 | Application of ligand of farnesol receptor |
CN201810200812.9A CN110251498A (en) | 2018-03-12 | 2018-03-12 | A class of compounds that regulate farnesoid receptor activity and uses thereof |
CN201810200812.9 | 2018-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018177151A1 true WO2018177151A1 (en) | 2018-10-04 |
Family
ID=63674152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/079472 WO2018177151A1 (en) | 2017-03-28 | 2018-03-19 | Compounds modulating activity of farnesoid x receptor and methods for the use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018177151A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022214691A1 (en) * | 2021-04-09 | 2022-10-13 | Immunic Ag | Deuterated dhodh inhibitors |
WO2023118576A1 (en) | 2021-12-23 | 2023-06-29 | Immunic Ag | Dhodh inhibitors containing a carboxylic acid bioisostere |
WO2024200872A1 (en) | 2023-03-29 | 2024-10-03 | Immunic Ag | Vidofludimus and related structures acting as nurr1 agonists |
WO2025003402A1 (en) | 2023-06-28 | 2025-01-02 | Immunic Ag | Heteroaromatic dhodh inhibitors |
WO2025036941A1 (en) | 2023-08-15 | 2025-02-20 | Immunic Ag | Oral pharmaceutical dosage form providing immediate release of vidofludimus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103097338A (en) * | 2010-07-01 | 2013-05-08 | 4Sc股份有限公司 | Novel salts as anti-inflammatory, immunomodulatory and antiproliferative agents |
-
2018
- 2018-03-19 WO PCT/CN2018/079472 patent/WO2018177151A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103097338A (en) * | 2010-07-01 | 2013-05-08 | 4Sc股份有限公司 | Novel salts as anti-inflammatory, immunomodulatory and antiproliferative agents |
Non-Patent Citations (1)
Title |
---|
SUN, XIUXIU ET AL.: "Progress of drug development for ulcerative colitis", WORLD CLINICAL DRUGS, vol. 34, no. 5, 31 May 2013 (2013-05-31), ISSN: 1672-9188 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022214691A1 (en) * | 2021-04-09 | 2022-10-13 | Immunic Ag | Deuterated dhodh inhibitors |
WO2023118576A1 (en) | 2021-12-23 | 2023-06-29 | Immunic Ag | Dhodh inhibitors containing a carboxylic acid bioisostere |
WO2024200872A1 (en) | 2023-03-29 | 2024-10-03 | Immunic Ag | Vidofludimus and related structures acting as nurr1 agonists |
WO2025003402A1 (en) | 2023-06-28 | 2025-01-02 | Immunic Ag | Heteroaromatic dhodh inhibitors |
WO2025036941A1 (en) | 2023-08-15 | 2025-02-20 | Immunic Ag | Oral pharmaceutical dosage form providing immediate release of vidofludimus |
WO2025036938A1 (en) | 2023-08-15 | 2025-02-20 | Immunic Ag | Oral pharmaceutical dosage form providing immediate release of vidofludimus |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018177151A1 (en) | Compounds modulating activity of farnesoid x receptor and methods for the use thereof | |
US10576091B2 (en) | Tomatidine, analogs thereof, compositions comprising same, and uses for same | |
CA2728219C (en) | Diglycidic ether derivative therapeutics and methods for their use | |
JP7021080B2 (en) | Farnesoid X Receptor Modulator | |
CN108883305B (en) | 3-deoxy derivatives and pharmaceutical compositions thereof | |
CN104688745B (en) | Method for inhibiting muscle atrophy | |
ES2847002T3 (en) | 11-hydroxyl-6-substituted derivatives of bile acids and amino acid conjugates thereof as modulators of the farnesoid X receptor | |
JP2015071626A (en) | Therapy of inflammation-related disease | |
US20180116993A1 (en) | Modulators of farnesoid x receptor and methods for the use thereof | |
Brun et al. | Peroxisome proliferator-activated receptor-γ mediates the anti-inflammatory effect of 3-hydroxy-4-pyridinecarboxylic acid derivatives: synthesis and biological evaluation | |
Lu et al. | A hydrogen peroxide responsive prodrug of Keap1-Nrf2 inhibitor for improving oral absorption and selective activation in inflammatory conditions | |
JP2014531402A5 (en) | ||
WO2011107023A1 (en) | Compounds for preventing and treating disorders of metabolism and uses thereof | |
Lu et al. | Discovery of 1, 8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways | |
Niu et al. | Association between endothelin-1/endothelin receptor A and inflammation in mouse kidneys following acute ischemia/reperfusion | |
Yue et al. | Discovery and evaluation of phenacrylanilide derivatives as novel potential anti-liver fibrosis agents | |
Aydin et al. | The melatonin agonist ramelteon attenuates bleomycin-induced lung fibrosis by suppressing the NLRP3/TGF-Β1/HMGB1 signaling pathway | |
JP7378156B2 (en) | 1,4-substituted isoquinoline inhibitors of KEAP1/NRF2 protein-protein interaction | |
WO2016121862A1 (en) | Anti-inflammatory drug and uses thereof | |
EP3160508B1 (en) | Novel rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18777022 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18777022 Country of ref document: EP Kind code of ref document: A1 |